Uncommon Causes of Movement Disorders


Uncommon Causes of Movement Disorders

A large number of neurological conditions result in abnormal movements of the body; these are often characterized by changes in coordination and altered speed of voluntary movement. Many obscure diseases, conditions and environmental insults can cause movement disorders but these are often overlooked. This volume expands and differentiates the many varied clinical presentations of movement disorders. Written by an international team of authors, including some of the most prominent clinicians in the field, disorders are defined and expanded in a clinically useful manner. Pathophysiological theories, genetic discoveries, new classifications, differential diagnoses and therapies are discussed extensively. Uncommon Causes of Movement Disorders provides a broad and comprehensive review of the field, concentrating on conditions infrequently seen but essential for practitioners to recognize in order to implement appropriate management. This is a key text for movement disorders specialists and general neurologists at all stages of their career.

Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, White LR, Aasly JO. Prevalence of haemochromatosis gene mutations in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78(3): 315–7.
Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708–12.
Aarsland D, Perry R, Larsen JP et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005; 66: 633–7.
Abdo WF, Borm GF, Munneke M et al. Ten steps to identify atypical parkinsonism. J Neurol Neurosurg Psychiatry 2006; 77: 1367–9.
Abel LA, Walterfang M, Fietz M, Bowman EA, Velakoulis D. Saccades in adult Niemann–Pick disease type C reflect frontal, brainstem, and biochemical deficits. Neurology 2009; 72(12): 1083–6.
Abetz L, Allen R, Follet A et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004; 26(6): 925–35.
Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the Restless Legs Syndrome Quality of Life questionnaire. Value Health 2005; 8(2): 157–67.
Abila B, Wilson JF, Marshall RW, Richens A. The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment. Br J Clin Pharmacol 1985; 20(4): 369–76.
Abuelo DN, Barsel-Bowers G, Tutschka BG et al. Symmetrical infantile thalamic degeneration in two sibs. J Med Genet 1981; 18: 448–50.
Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord 2007; 13(Suppl 3): S362–8.
Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. Arch Neurol Psychiatry 1959; 81: 154–72.
Adler CH. Sports-related task-specific dystonia: the yips. In: Stacy M, ed. Handbook of Dystonia. New York: Informa Healthcare; 2007.
Adler CH. Strategies for controlling dystonia. Postgrad Med 2000; 108: 151–60.
Aizawa H, Kwak S, Shimizu T et al. A case of adult onset pure pallidal degeneration. I. Clinical manifestations and neuropathological observations. J Neurol Sci 1991; 102: 76–82.
Akagi H, Kumar TM. Lesson of the week: akathisia: overlooked at a cost. BMJ 2002; 324: 1506–7.
Al Chalabi A, Durr A, Wood NW et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009; 4: e7114.
Al-Asmi A, Jansen AC, Badhwar A et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia 2005; 46: 1256–63.
Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005; 41: 668–70.
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007; 369(9559): 397–408.
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson's disease. Lancet 2007; 369: 397–408.
Ala TA, Hughes LF, Kyrouac GA et al. Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70(4): 483–8.
Alam M, Smith G, Bleasdale-Barr K, Pavitt DV, Mathias CJ. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens 1995; 13: 1664–9.
Alarcón F, Zijlmans JC, Dueñas G, Cevallos N. Post-stroke movement disorders: report of 56 patients. J Neurol Neurosurg Psychiatry 2004; 75(11): 1568–74.
Albanese A, Barnes MP, Bhatia KP et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13: 433–44.
Albanese A, Filippini G. Gabapentin improved sensory and motor symptoms in the restless legs syndrome. ACP J Club 2003; 139(1): 17.
Albanese A. The clinical expression of primary dystonia. J Neurol 2003; 250: 1145–51.
Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 2002; 40(6): 559–64.
Albin RL, Koeppe RA, Wernette K et al. Striatal [11C]dihydrotetrabenazine and [11C]mehylphenidate binding in Tourette syndrome. Neurology 2009; 72: 1390–6.
Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357–81.
Allan LM, Ballard CG, Allen J et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007; 78: 671–7.
Allen FH, Krabbe SM, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang 1961; 6: 555–60.
Allen M, Sandelberg-Wolheim M, Sjogren K et al. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol 1994; 39: 41–8.
Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56(2): 263–5.
Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19(3): 205–13.
Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000; 1(1): 11–9.
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4(2): 101–19.
Allen RP, Walters AS, Montplaisir J et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165(11): 1286–92.
Allen RP. Article reviewed: Restless legs syndrome in monozygotic twins: clinical correlates. Sleep Med 2001; 2(2): 169–71.
Allen RP. Improving RLS diagnosis and severity assessment: polysomnography, actigraphy and RLS-sleep log. Sleep Med 2007; 8(Suppl 2): S13–8.
Almasy L, Bressman S, De Leon D. Ethnic variation in the clinical expression of idiopathic torsion dystonia. Mov Disord 1997; 12: 715–21.
Almasy L, Bressman SB, Raymond D et al. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 1997; 42: 670–3.
Almer G, Hainfellner JA, Brucke T et al. Fatal familial insomnia: a new Austrian family. Brain 1999; 122(Pt 1): 5–16.
Alonso ME, Teixeira F, Jimenez G et al. Chorea-acanthocytosis: report of a family and neuropathological study of two cases. Can J Neurol Sci 1989; 16: 426–31.
Alp R, Ilhan Alp S, Ure H. Two intracranial sewing needles in a young woman with hemi-chorea. Parkinsonism Relat Disord 2009; 15: 795–6.
Altinos N, Kars Z, Cepoglu C. Rare causes of hemifacial spasm: report of two cases. Clin Neurol Neurosurg 1991; 93: 155–8.
Altrocchi PH, Forno LS. Spontaneous oral-facial dyskinesia: neuropathology of a case. Neurology 1983; 33: 802–5.
Alty JE, Clissold BG, McColl CD, Reardon KA, Shiff M, Kempster PA. Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function. Mov Disord 2009; 24: 2337–43.
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162–7.
Amador SC, Hood AJ, Schiess MC, Izor R, Sereno AB. Dissociating cognitive deficits involved in voluntary eye movement dysfunctions in Parkinson's disease patients. Neuropsychologia 2006; 44(8): 1475–82.
Amato AA, Gronseth GS, Jackson CE et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40: 581–6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 2000.
Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994; 55: 394–400.
Anca MH, Zaccai TF, Badarna S et al. Natural history of Oppenheim's dystonia (DYT1) in Israel. J Child Neurol 2003; 18: 325–30.
Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients. Mov Disord 2008; 23(7): 977–84.
Andrade DM, Hamani C, Minassian BA. Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus. Expert Opin Pharmacother 2009; 10: 1549–60.
Andrew J, Fowler CJ, Harrison MJG, Kendall BE. Post-traumatic tremor due to vascular injury and its treatment by stereotactic thalamotomy. J Neurol Neurosurg Psychiatry 1982; 45: 560.
Angles A, Bagheri H, Saivin S et al. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease. Therapie 2002; 57: 408–10.
Anheim M, Fleury M, Monga B G et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics 2010; 11(1): 1–12.
Anheim M, Monga B, Fleury M et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. Brain 2009; 132(Pt 10): 2688–98.
Aniello MS, Martino D, Petruzzella V et al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov Disord 2008; 23(1): 114–8.
Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf 2009; 32(6): 475–88.
Aramideh M, Ongerboer de Visser BW, Koelman JH et al. Clinical and electromyographic features of levator palpebrae superioris muscle dysfunction in involuntary eyelid closure. Mov Disord 1994; 9(4): 395–402.
Ardouin C, Voon V, Worbe Y et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21(11): 1941–6.
Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathol 1992; 83: 453–60.
Armand S, Mercier M, Watelain E et al. A comparison of gait in spinal muscular atrophy, type II and Duchenne muscular dystrophy. Gait Posture 2005; 21: 369–78.
Armstrong IT, Chan F, Riopelle RJ, Munoz DP. Control of saccades in Parkinson's disease. Brain Cogn 2002; 49(2): 198–201.
Armstrong RA, Cairns NJ, Lantos PL. Multiple system atrophy (MSA): topographic distribution of the alpha-synuclein-associated pathological changes. Parkinsonism Relat Disord 2006; 12: 356–62.
Armstrong RA, Lantos PL, Cairns NJ. Spatial patterns of alpha-synuclein positive glial cytoplasmic inclusions in multiple system atrophy. Mov Disord 2004; 19: 109–12.
Armstrong, DM. The supraspinal control of mammalian locomotion. J Phys 1988; 102: 2–13.
Asai H, Hirano M, Shimada K et al. Protein kinase C{gamma}, a protein causative for dominant ataxia, negatively regulates nuclear import of recessive-ataxia-related aprataxin. Hum Mol Genet 2009; 18(19): 3533–43.
Asbahr FR, Garvey MA, Snider LA et al. Obsessive-compulsive symptoms among patients with Sydenham chorea. Biol Psychiatry 2005; 57: 1073–6.
Asbahr FR, Negrao AB, Gentil V et al. Obsessive-compulsive and related symptoms in children and adolescents with rheumatic fever with and without chorea: a prospective 6-month study. Am J Psychiatry 1998; 155: 1122–4.
Aschner M, Erikson KM, Hernández EH, Tjalkens R. Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromol Med 2009; 11(4): 252–66.
Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41: 479–81.
Asherson RA, Cervera R. The antiphospholipid syndrome: multiple faces beyond the classical presentation. Autoimmun Rev 2003; 2: 140–51.
Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142: 385–90.
Asmus F, Hjermind LE, Dupont E et al. Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain 2007; 130: 2736–45.
Asmus F, Zimprich A, Tezenas Du MS et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002; 52: 489–92.
Atkinson MJ, Allen RP, DuChane J, Murray C, Kushida C, Roth T. Validation of the Restless Legs Syndrome Quality of Life Instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation. Qual Life Res 2004; 13(3): 679–93.
Auger RG, Litchy Wj, Cascino TL et al. Hemimasticatory spasm: clinical and electrophysiological observations. Neurology 1992; 42: 2263–6.
Auger RG, Piepgras DG. Hemifacial spasm associated with epidermoid tumors of the cerebellopontine angle. Neurology 1989; 39: 577–80.
Auger RG. Hemifacial spasm: clinical and electrophysiologic observations. Neurology 1979; 29: 1261–72.
Augood SJ, Keller-McGandy CE, Siriani A et al. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Res 2003; 986: 12–21.
Avanzino L, Martino D, van de Warrenburg BP et al. Cortical excitability is abnormal in patients with the “fixed dystonia” syndrome. Mov Disord 2008; 23: 646–52.
Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 206–13.
Ayoub EM, Barrett DJ, Maclaren NK, Krischer JP. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest 1986; 77: 2019–26.
Azevedo LL, Cardoso F, Reis C. Acoustic analysis of prosody in females with Parkinson's disease: comparison with normal controls. Arq Neuropsiquiatr 2003; 61: 999–1003.
Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb ClinNeurol 2008; 89: 461–73.
Bacsi AM, Fung VS, Colebatch JG. Sway patterns in orthostatic tremor: impairment of postural control mechanisms. Mov Disord 2005; 20(11): 1469–75.
Bader B, Arzberger T, Heinsen H et al. Neuropathology of chorea-acanthocytosis. In: Walker RH, Saiki S, Danek A, eds. Neuroacanthocytosis Syndromes II. Berlin, Heidelberg: Springer-Verlag; 2008: 187–95.
Bader B, Walker RH, Vogel M et al. Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. Mov Disord 2010; 25(1): 127–9.
Bae SH, Vates TS Jr, Kenton EJ. Generalized chorea associated with chronic subdural hematomas. Ann Neurol 1980; 8(4): 449–50.
Baekkeskov S, Aanstoot H-J, Christgau S et al. Identification of the 64 K autoantigen in insulin dependent diabetes mellitus as the GABA synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151–6.
Baik JS, Lang AE. Gait abnormalities in psychogenic movement disorders. Mov Disord 2007; 22: 395–9.
Baik JS, Lang AE. Gait abnormalities in psychogenic movement disorders. Mov Disord 2007; 22: 395–9.
Bain PG, Findley LJ, Britton TC, Rothwell JC et al. Primary writing tremor. Brain 1995; 118: 1461–72.
Bain PG. The effectiveness of treatments for essential tremor. Neurologist 1997; 305–21.
Bain PG. Tremor. Parkinsonism Relat Disord 2007; 13(Suppl 3): S369–74.
Baker MR, Das M, Isaacs J, Fawcett PR, Bates D. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005; 76: 999–1001.
Bakheit A. The syndrome of motor restlessness – a treatable but under-recognised disorder. Postgrad Med J 1997; 73: 529–30.
Balas I, Kovacs N, Hollody K. Staged bilateral stereotactic pallidothalamotomy for life-threatening dystonia in a child with Hallervorden–Spatz disease. Mov Disord 2006; 21(1): 82–5.
Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 1999; 10: 97–103.
Bancroft J, Vukadinovic Z. Sexual addiction, sexual compulsivity, sexual impulsivity, or what? Toward a theoretical model. J Sex Res 2004; 41(3): 225–34.
Bandt SK, Anderson D, Biller J. Deep brain stimulation as an effective treatment option for post-midbrain infarction-related tremor as it presents with Benedikt syndrome. J Neurosurg 2008; 109(4): 635–9.
Baquis GD, Pessin MS, Scott RM. Limb shaking – a carotid TIA. Stroke 1985; 16: 444–8.
Barash J, Margalith D, Matitiau A. Corticosteroid treatment in patients with Sydenham's chorea. Pediatr Neurol 2005; 32: 205–7.
Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000; 54: 1304–9.
Barbosa ER, Bittar MS, Bacheschi LA, Comerlatti LR, Scaff M. Precocious Parkinson's disease associated with “eye-of-the-tiger” type pallidal lesions. Arq Neuropsiquiatr 1995; 53(2): 294–7.
Barbosa ER, Silveira-Moriyama L, Machado AC, Bacheschi LA, Rosemberg S, Scaff M. Wilson's disease with myoclonus and white matter lesions. Parkinsonism Relat Disord 2007; 13: 185–8.
Bardutzky J, Tronnier V, Schwab S, Meinck HM. Intrathecal baclofen for stiff-person syndrome: life- threatening intermittent catheter leakage. Neurology 2003; 60: 1976–8.
Barker RA, Revesz T, Thom M et al. Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998; 655: 633–640.
Barraquer-Bordas L, Zamora S, Abello-Villa P. Espasmo hemifacial y sordera central bilateral en el cuadro clinic de una siringobulbia. Rev Esp Oto Oftalmol 1955; 17: 17–22.
Barreiro De Madariaga LM, Sian J, Casas Parrera I, Micheli F. Arm chorea secondary to an unruptured giant aneurysm. Mov Disord 2003; 18(11): 1397–9.
Barsottini OG, Ferraz HB, Seviliano MM, Barbieri A. Brain SPECT imaging in Sydenham's chorea. Braz J Med Biol Res 2002; 35: 431–6.
Bartell S, Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med 2006; 2(2): 187–8.
Barthel H, Hermann W, Kluge R et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol 2003; 24(2): 234–8.
Basso A, Luzzatti C, Spinnler H. Is ideomotor apraxia the outcome of damage to well-defined regions of the left hemisphere? Neuropsychological study of CAT correlation. J Neurol Neurosurg Psychiatry 1980; 43(2): 118–26.
Baumeister FA, Auer DP, Hortnagel K, Freisinger P, Meitinger T. The eye of the tiger sign is not a reliable disease marker for Hallervorden–Spatz syndrome. Neuropediatrics 2005; 36(3): 221–2.
Bawden M, Maynard I. Towards an understanding of the personal experience of the “yips” in cricketers. J Sports Sci 2001; 19(12): 937–53.
Baysal L, Acarer A, Celebisoy N. Post-ischemic Holmes' tremor of the lower extremities. J Neurol 2009; 256(12): 2079–81.
Beato R, Maia D, Teixeira A, Cardoso F. Executive functioning in adult patients with Sydenham's chorea. Mov Disord 2010; 25(7): 853–7.
Becher MW, Rubinsztein DC, Leggo J et al. Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov Disord 1997; 12: 519–30.
Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994; 151: 1336–41.
Becker W, Jurgens R, Kassubek J, Ecker D, Kramer B, Landwehrmeyer B. Eye–head coordination in moderately affected Huntington's disease patients: do head movements facilitate gaze shifts? Exp Brain Res 2009; 192(1): 97–112.
Ben Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997; 48: 384–93.
Benbadis IE, Bhatia KP, Lopes-Cendes I, et al. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet 1994, 343(8896): 515–171.
Benbadis SR. Psychogenic nonepileptic seizures. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice, 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2010: 486–94.
Benito-León J. Symptomatic orthostatic tremor in pontine lesions. Neurology 1997; 49: 1439–41.
Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132: 156–71.
Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain 1998; 121(Pt 7): 1195–212.
Berciano J, Boesch S, Perez-Ramos JM, Wenning GK. Olivopontocerebellar atrophy: toward a better nosological definition. Mov Disord 2006; 21(10): 1607–13.
Bergmann KJ, Salak VL. Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14(4): 348–52.
Bergmann M, Kuchelmeister K, Migheli A et al. Motor neuron disease with pallido-luysio-nigral atrophy. Acta Neuropathol 1993; 86: 105–8.
Berk C, Carr J, Sinden M, Martzke J, Honey CR. Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life. J Neurosurg 2002; 97: 815–20.
Berkovic SF, Carpenter S, Andermann F, Andermann E, Wolfe LS. Kufs' disease: a critical reappraisal. Brain 1988; 111(Pt 1): 27–62.
Berlit P. Neuropsychiatric disease in collagen vascular diseases and vasculitis. J Neurol 2007; 254(Suppl 2): II87–9.
Bessiere D, Lacroix C, Campagne S et al. Structure-function analysis of the THAP zinc finger of THAP1, a large C2CH DNA-binding module linked to Rb/E2F pathways. J Biol Chem 2008; 283: 4352–63.
Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord 1996; 11: 324–6.
Bhatia K, Daniel SE, Marsden CD. Orofacial dystonia and rest tremor in a patient with normal brain pathology. Mov Disord 1993; 8: 361–2.
Bhayani R, Goel A. Occipital falcine meningioma presenting with ipsilateral hemifacial spasm: a case report. Br J Neurosurg 1996; 10: 603–5.
Biancheri R, Ciccolella M, Rossi A et al. White matter lesions in spastic paraplegia with mutations in SPG5/ CYP7B1. Neuromuscul Disord 2009; 19: 62–5.
Biancheri R, Ciccolella M, Rossi A et al. White matter lesions in spastic paraplegia with mutations in SPG5/CYP7B1. Neuromuscul Disord 2009; 19(1): 62–5.
Bill DC, Hanieh A. Hemifacial spasm in an infant due to 4th ventricular ganglioglioma. J Neurosurg 1991; 75: 134–7.
Biller B, Graff-Radoford NR, Smoker WRK, Adams Jr. HP, Johnston P. MR imaging in “lacunar” hemiballismus. J Comput Assist Tomogr 10(5): 793–7.
Bimpong-Buta K, Froescher W. Carbamazepine-induced choreoathetoid dyskinesias. J Neurol Neurosurg Psychiatry 1982; 45: 560.
Binder J, Hofmann S, Kreisel S et al. Clinical and molecular findings in a patient with a novel mutation in the deafness-dystonia peptide (DDP1) gene. Brain 2003; 126: 1814–20.
Bindoff LA, Birch-Machin MA, Farnsworth L, Gardner-Medwin D, Lindsay JG, Turnbull DM. Familial intermittent ataxia due to a defect of the E1 component of pyruvate dehydrogenase complex. J Neurol Sci 1989; 93(2–3): 311–8.
Binzer M, Eisemann M. Childhood experiences and personality traits in patients with motor conversion symptoms. Acta Psychiatr Scand 1998; 98: 288–95.
Binzer M, Kullgren G. Motor conversion disorder. A prospective 2- to 5-year follow-up study. Psychosomatics 1998; 39: 519–27.
Bithell A, Johnson R, Buckley NJ. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease. Biochem Soc Trans 2009; 37(Pt 6): 1270–5.
Black DN, Seritan AL, Taber KH, Hurley RA. Conversion hysteria: lessons from functional imaging. J Neuropsychiatry Clin Neurosci 2004; 16: 245–51.
Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004; 187: 455–9.
Blayac JP, Pinzani V, Peyriere H et al. Drug-induced movement disorders: tardive syndromes. Therapie 2004; 59: 113–19.
Blin J, Vidailhet MJ, Pillon B et al. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992; 7(4): 348–54.
Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol 2001; 248: 950–8.
Blondel A, Eustache F, Schaeffer S et al. [Clinical and cognitive study of apraxia in cortico-basal atrophy. A selective disorder of the production system]. Rev Neurol (Paris) 1997; 153(12): 737–47.
Blum P, Jankovic J. Stiff person syndrome: an autoimmune disease. Mov Disord 1991; 6: 12–20.
Blunt SB, Brooks DJ, Kennard C. Steroid-responsive chorea in childhood following cardiac transplantation. Mov Disord 1994; 9(1): 112–14.
Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 72: 300–3.
Boeve BF, Josephs KA, Drubach DA. Current and future management of the corticobasal syndrome and corticobasal degeneration. Handb Clin Neurol 2008; 89: 533–48.
Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54(Suppl 5): S15–19.
Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54(Suppl 5): S15–9.
Boeve BF, Maraganore DM, Parisi JE et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999; 53(4): 795–800.
Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16: 622–30.
Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986; 13(3): 245–7.
Bohlega S, Tanji K, Santorelli F et al. Multiple mitochondrial DNA deletions associated with autosomal recessive ophthalmoplegia and severe cardiomyopathy. Neurology 1996; 46: 1329–34.
Bonnet C, Augustin S, Ellouze S et al. The optimized allotopic expression of ND1 or ND4 genes restores respiratory chain complex I activity in fibroblasts harboring mutations in these genes. Biochim Biophys Acta 2008; 1783: 1707–17.
Bonuccelli U, Nocchiero A, Napolitano A et al. Domperidone-induced acute dystonia and polycystic ovary syndrome. Mov Disord 1991; 6: 79–81.
Boon M, Nolte IM, Bruinenberg M et al. Mapping of a susceptibility gene for multiple sclerosis to the 51 kb interval between G%11525 and D651666 using a new method of haplotype sharing analysis. Neurogenetics 2001; 3: 221–30.
Borghese NA, Bianchi L, Lacquanti F. Kinematic determinants of human locomotion. J Physiol 1996; 494: 863–79.
Borroni B, Garibotto V, Agosti C et al. White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia. Arch Neurol 2008; 65(6): 796–801.
Borroni B, Grassi M, Costanzi C, Archetti S, Caimi L, Padovani A. APOE genotype and cholesterol levels in Lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk. Am J Geriatr Psychiatry 2006; 14: 1022–31.
Borroni B, Malinverno M, Gardoni F et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008; 71(22): 1796–803.
Bostwick JM, Kathleen AH, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic parkinson disease. Mayo Clin Proc 2009; 84(4): 310–6.
Bouvette CM, McPhee BR, OpferGehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc 1996; 71: 847–53.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49(5): 1284–8.
Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49: 1284–8.
Bower JH, Muenter MD. Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma. Mov Disord 1995; 10: 681–2.
Bowers MB, Jr., Heninger GR. Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment. Psychiatry Res 1981; 4: 285–90.
Boxer AL, Garbutt S, Rankin KP et al. Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration. J Neurosci 2006; 26(23): 6354–63.
Boxer AL, Geschwind MD, Belfor N et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63(1): 81–6.
Boxer AL, Geschwind MD, Belfor N et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63(1): 81–6.
Boycott KM, Bonnemann C, Herz J et al. Mutations in VLDLR as a cause for autosomal recessive cerebellar ataxia with mental retardation (dysequilibrium syndrome). J Child Neurol 2009; 24(10): 1310–5.
Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21(12): 2042–51.
Braak H, Del Tredici K, Rub U, de Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211.
Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70(20): 1916–25.
Braak H, Muller CM, Rub U et al. Pathology associated with sporadic Parkinson's disease – where does it end? J Neural Transm Suppl 2006; (70): 89–97.
Braak H, Rub U, Sandmann-Keil D et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 2000; 99: 489–95.
Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004; 75: 382–7.
Brashear A, Dobyns WB, de Carvalho AP et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007; 130: 828–35.
Brazis PW. Masdeu JC. Biller J. Localization in Clinical Neurology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
Bressman SB, Raymond D, Fuchs T et al. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 2009; 8: 441–6.
Bressman SB, Sabatti C, Raymond D et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000; 54: 1746–52.
Brewer GJ, Askari F, Dick RB et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Translational Research: J Lab Clin Med 2009; 154: 70–7.
Brewer GJ, Askari F, Lorincz MT et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63: 521–7.
Brewer GJ, Askari FK. Wilson's disease: clinical management and therapy. J Hepatol 2005; 42(Suppl 1): S13–21.
Brewer GJ, Hedera P, Kluin KJ et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60: 379–85.
Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 1983; 99: 314–9.
Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44(5): 490–3.
Brewer GJ. Penicillamine should not be used as initial therapy in Wilson's disease. Mov Disord 1999; 14: 551–4.
Briand KA, Strallow D, Hening W, Poizner H, Sereno AB. Control of voluntary and reflexive saccades in Parkinson's disease. Exp Brain Res 1999; 129(1): 38–48.
Brin MF, Hays A, Symmans WA et al. Neuropathology of McLeod phenotype is like chorea-acanthocytosis (CA). Can J Neurol Sci 1993; 20(Suppl 4): 234.
Brockmann K, Simpson MA, Faber A et al. Complicated hereditary paraplegia with thin corpus callosum and childhood onset. Neuropediatrics 2005; 36: 274–8.
Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev 2009; 31(7): 545–52.
Bronstein AM, Mossman S, Luxon LM. The neck-eye reflex in patients with reduced vestibular and optokinetic function. Brain 1991; 114(Pt 1A): 1–11.
Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol 1993; 151: 2820–8.
Brooks D, Halliday GM. Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull 2009; 78: 97–104.
Brooks DE. Propofol-induced movement disorders. Ann Emerg Med 2008; 51: 111–12.
Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28(4): 547–55.
Brown P, Day BL, Rothwell JC et al. Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. Brain 1991; 114: 2333.
Brown P, Funk SC. Tardive dyskinesia: barriers to the professional recognition of an iatrogenic disease. J Health Soc Behav 1986; 27: 116–32.
Brown P, Marsden CD. The stiff-man and stiff-man plus syndromes. J Neurol 1999; 246: 648–52.
Brown P, Thompson PD. Electrophysiological aids to the diagnosis of psychogenic jerks, spasms, and tremor. Mov Disord 2001; 16: 595–9.
Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect 2005; 113: 1250–6.
Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS Pesticides and Parkinson's disease – is there a link? Environ Health Perspect 2006; 114(2): 156–64.
Brunberg JA. Ataxia. AJNR Am J Neuroradiol 2008; 29(7): 1420–2.
Bruns L. Uber storungen des gleichgewichts bei stirnhirntumoren. Dtsch Med Wschr 1892; 18: 138–43.
Brusse E, Maat-Kievit JA, van Swieten JC. Diagnosis and management of early- and late-onset cerebellar ataxia. Clin Genet 2007; 71(1): 12–24.
Bruyn GW, Ferrari MD. Chorea and migraine: “Hemicrania choreatica”? Cephalalgia 1984; 4(2): 119–24.
Buechner S, Teresa M, De Cristofaro R, Ramat S, Borsini W. Parkinsonism and Anderson Fabry's disease: a case report. Mov Disord 2006; 21(1): 103–7.
Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999; 9(4): 681–93.
Bugiani O, Murrell JR, Giaccone G et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999; 58(6): 667–77.
Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327–37.
Burbaud P, Rougier A, Ferrer X et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord 2002; 17: 204–7.
Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord 2005; 20: 1681–2.
Burke RE, Fahn S, Jankovic J et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–46.
Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899–907.
Burn DJ, Rowan EN, Allan LM, Molloy S, T O'Brien J, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. Journal of Neurology Neurosurgery and Psychiatry 2006; 77: 585–9.
Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele–Richardson–Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57(3): 278–84.
Buschdorf JP, Chew LL, Soh UJ, Liou YC, Low BC. Nerve growth factor stimulates interaction of Cayman ataxia protein BNIP-H/Caytaxin with peptidyl-prolyl isomerase Pin1 in differentiating neurons. PLoS One 2008; 3(7): e2686.
Butler MH, Hayashi A, Ohkoshi N et al. Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000; 26: 307–12.
Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 2006; 7(10): 784–96.
Buttner N, Geschwind D, Jen JC, Perlman S, Pulst SM, Baloh RW. Oculomotor phenotypes in autosomal dominant ataxias. Arch Neurol 1998; 55(10): 1353–7.
Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363–84.
Callaghan N. Restless legs syndrome in uremic neuropathy. Neurology 1966; 16(4): 359–61.
Caparros-Lefebvre D, Destee A, Petit H. Late onset familial dystonia: could mitochondrial deficits induce a diffuse lesioning process of the whole basal ganglia system. J Neurol Neurosurg Psychiatry 1997; 63(2): 196–203.
Caparros-Lefebvre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 1999; 354(9175): 281–6.
Carbon M, Niethammer M, Peng S et al. Abnormal striatal and thalamic dopamine neurotransmission: Genotype-related features of dystonia. Neurology 2009; 72: 2097–103.
Cardoso F, Dornas L, Cunningham M, Oliveira JT. Nerve conduction study in Sydenham's chorea. Mov Disord 205; 20: 360–3.
Cardoso F, Jankovic J, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery 1995; 36: 501–7.
Cardoso F, Maia D, Cunningham MC, Valenca G. Treatment of Sydenham chorea with corticosteroids. Mov Disord 2003; 18: 1374–7.
Cardoso F, Oliveira PM, Reis CC et al. Prosody in Sydenham chorea – I: Tessitura. Mov Disord 2006; 21: S359–60.
Cardoso F, Oliveira PM, Reis CC et al. Prosody in Sydenham chorea – II: Duration of statements. Mov Disord 2006; 21: S360.
Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol 2006; 5: 589–602.
Cardoso F, Silva CE, Mota CC. Sydenham's chorea in 50 consecutive patients with rheumatic fever. Mov Disord 1997; 12: 701–3.
Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV. Persistent Sydenham's chorea. Mov Disord 1999; 14: 805–7.
Cardoso F. Chorea gravidarum. Arch Neurol 2002; 59: 868–70.
Cardoso F. Chorea. In: Hallett M, Poewe W, eds. Therapeutics of Parkinson's Disease and Other Movement Disorders. Philadelphia: Wiley; 2008: 212–27.
Cardoso F. HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs 2002; 16(10): 663–8.
Cardoso F. HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs 2002; 16: 663–8.
Cardoso F. Sydenham's chorea. Curr Treat Options Neurol 2008; 10: 230–5.
Carella F, Ciano C, Panzica F, Scaioli V. Myoclonus in corticobasal degeneration. Mov Disord 1997; 12(4): 598–603.
Cartwright GE. Diagnosis of treatable Wilson's disease. N Engl J Med 1978; 298: 1347–50.
Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia dY, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 2006; 97: 934–46.
Casari G, Rugarli E. Molecular basis of inherited spastic paraplegias. Curr Opin Gen Dev 2001; 11: 336–42.
Case records of the Massachusetts General Hospital. weekly clinicopathological exercises. case 38–1985. A 66-year-old man with progressive neurologic deterioration. N Engl J Med 1985; 313(12): 739–48.
Casey DE. Neuroleptic-induced acute dystonia. In: Lang AE, Weiner WJ, eds. Drug-induced Movement Disorders. Mount Kisko, NY, Futura; 1992: 21–40.
Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65(Suppl 9): 25–8.
Casey DE. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985; 46: 42–7.
Casey DE. Tardive dyskinesia. West J Med 1990; 153: 535–41.
Castelnau P, Cif L, Valente EM et al. Pallidal stimulation improves pantothenate kinase-associate neurodegeneration. Ann Neurol 2005; 57(5): 738–41.
Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P. Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997; 27: 358–62.
Caviness JN, Alving LI, Maranganore DM et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 1999; 74: 5665–69.
Caylak E. The genetics of sleep disorders in humans: narcolepsy, restless legs syndrome, and obstructive sleep apnea syndrome. Am J Med Genet A 2009; 149A(11): 2612–26.
Cayrol C, Lacroix C, Mathe C et al. The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood 2007; 109.
Cazzoli D, Muri RM, Hess CW, Nyffeler T. Horizontal and vertical dimensions of visual extinction: a theta burst stimulation study. Neuroscience 2009; 164(4): 1609–14.
Ceballos-Picot I, Mockel L, Potier MC et al. Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch–Nyhan disease pathogenesis. Hum Mol Genet 2009 1; 18(13): 2317–27.
Cervenka S, Palhagen SE, Comley RA et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006; 129(Pt 8): 2017–28.
Chabli A, Michaud M, Montplaisir J. Periodic arm movements in patients with the restless legs syndrome. Eur Neurol 2000; 44(3): 133–8.
Chaila EC, McCabe DJH, Delanty N, Costello DJ, Murphy RP. Broadening the phenotype of childhood-onset dopa-responsive dystonia. Arch Neurol 2006; 63(8): 1185–8.
Chalk CH, Litchy WJ, Ebersold MH et al. Facial myokymia and unilateral basilar invagination. Neurology 1988; 38: 1811–12.
Chalk JB, Patterson MC, Pender MP. An intracranial arteriovenous malformation and palatal myoclonus related to pseudoxanthoma elasticum. Aust N Z J Med 1989; 19(2): 141–3.
Chan CH, Briellmann RS, Pell GS et al. Thalamic atrophy in childhood absence epilepsy. Epilepsia 2006; 47: 399–405.
Chan F, Armstrong IT, Pari G, Riopelle RJ, Munoz DP. Deficits in saccadic eye-movement control in Parkinson's disease. Neuropsychologia 2005; 43(5): 784–96.
Chan KY, Lam CW, Lee LP, Tong SF, Yuen YP. Panthothenate kinase-associated neurodegeneration in two Chinese children: identification of a novel PANK2 gene mutation. Hong Kong Med J 2008; 14(1): 70–3.
Chang VC, Frucht, SJ. Myoclonus. Curr Treat Options Neurol 2008; 10: 222–9.
Charcot JM. Histologie de le sclérose en plaques. Gaz Hȏp Civils Milit (Paris) 1868; 41: 554–5, 557–8, 556.
Charcot JM. Histologie de le sclérose en plaques. Gaz Hȏp Paris 1868; 141: 554–5, 557–8, 566.
Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72(3): 1327–30.
Cherian A, Thomas B, Baheti NN, Chemmanam T, Kesavadas C. Concepts and controversies in nonketotic hyperglycemia-induced hemichorea: further evidence from susceptibility-weighted MR imaging. J Magn Reson Imaging 2009; 29: 699–703.
Ching KH, Westaway SK, Gitschier J et al. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002; 58: 1673–4.
Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with panthothenate kinase-associated neurodegeneration. Neurology 2002; 58(11): 1673–4.
Chinnery P, Johnson M, Wardell T et al. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000; 48: 188–93.
Chinnery P, MaJAMAa K, Turnbull D et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006; CD004426.
Chinnery PF, Crompton DE, Birchall D et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130(Pt 1): 110–9.
Chinnery PF, Crompton DE, Birchall D et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130: 110–19.
Chinnery PF, Curtis AR, Fey C et al. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet 2003; 40(5): e69.
Chinnery PF. Neuroferritinopathy. 2007 Aug 8. Available at: www.genetests.org (accessed May 8, 2009).
Cho YW, Shin WC, Yun CH et al. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008; 31(2): 219–23.
Choi SJ, Lee SW, Kim MC et al. Posteroventral pallidotomy in medically intractable postapoplectic monochorea: case report. Surg Neurol 2003; 59: 486–90.
Choi SM, Lee SH, Park MS, Kim BC, Kim MK, Cho KH. Disappearance of resting tremor after thalamic stroke involving the territory of the tuberothalamic artery. Parkinsonism Relat Disord 2008; 14(4): 373–5.
Chouza C, Scaramelli A, Caamano JL et al. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986; 1: 1303–4.
Chu K, Kang DW, Kim DE, Park SH, Roh JK. Diffusion-weighted and gradient echo magnetic resonance findings of hemichorea-hemiballismus associated with diabetic hyperglycemia: a hyperviscosity syndrome? Arch Neurol 2002; 59: 448–52.
Chung WS, Chiu HP. Drug-induced akathisia revisited. Br J Clin Pract 1996; 50: 270–8.
Church AJ, Cardoso F, Dale RC et al. Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology 2002; 59: 227–31.
Church AJ, Dale RC, Cardoso F et al. CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome? J Neuroimmunol 2003; 136(1–2): 149–53.
Cif L, Biolsi B, Gavarini S, et al. Antero-ventral internal pallidum stimulation improves behavioral disorders in Lesch–Nyhan disease. Mov Disord 2007; 22(14): 2126–9.
Cilia R, Siri C, Marotta G et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 2008; 65(12): 1604–11.
Citak EC, Gukuyener K, Karabacak NI et al. Functional brain imaging in Sydenham's chorea and streptococcal tic disorders. J Child Neurol 2004; 19: 387–90.
Claperon A, Hattab C, Armand V et al. The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system. Brain Res 2007; 1147: 12–24.
Clark JD, Elliott J. A case of a methadone-induced movement disorder. Clin J Pain 2001; 17: 375–7.
Clark LN, Kartsaklis LA, Gilbert RW et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66: 578–83.
Clark MR Psychogenic disorders: a pragmatic approach for formulation and treatment. Semin Neurol 2006; 26: 357–65.
Clot F, Grabli D, Cazeneuve C et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain 2009; 132(Pt 7): 1753–63.
Coccagna G, Lugaresi E. Restless legs syndrome and nocturnal myoclonus. Int J Neurol 1981; 15(1–2): 77–87.
Cockerell OC, Rothwell J, Thompson PD, Marsden CD, Shorvon SD. Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain 1996; 119(Pt 2): 393–407.
Cogan DG, Adams RD. A type of paralysis of conjugate gaze (ocular motor apraxia). AMA Arch Ophthalmol 1953; 50(4): 434–42.
Cogan DG. A type of congenital ocular motor apraxia presenting jerky head movements. Am J Ophthalmol 1953; 36(4): 433–41.
Colosimo C, Merello M, Pontieri FE. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J Neurol 1996; 243: 422–5.
Combarros O, Gutiérrez A, Pascual J, Berciano J. Oral dyskinesias associated with bilateral thalamocapsular infarction. J Neurol Neurosurg Psychiatry 1990; 53: 168–9.
Combarros O, Infante J, Llorca J, Berciano J. Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord 2003; 18: 1385–6.
Compston A, Confavreux C, Lassmann H et al. The genetics of multiple sclerosis. In: Compston A, McDonald IR, Noseworthy J et al., eds. McAlpine's Multiple Sclerosis. 4th ed. Philadelphia: Churchill Livingstone/Elsevier, 2005: 113–81.
Connor JR, Boyer PJ, Menzies SL et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61(3): 304–9.
Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 2010; 16(2): 142–45.
Contamin F, Escourolle R, Nick J et al. Atrophie pallido-nigro-luysienne: syndrome akinétique avec palilalie, rigidité oppositonnelle et catatonie. Rev Neurol 1971; 124: 107–20.
Cooper CA, Jadidian A, Paggi M et al. Prevalence of hypersexual behavior in Parkinson's disease patients: not restricted to males and dopamine agonist use. J Gen Med 2009; 2: 57–61.
Cormack F, Aarsland D, Ballard C et al. Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2004; 19(4): 371–7.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–25.
Cortelli P, Perani D, Montagna P et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain 2006; 129: 668–75.
Couprie W, Wijdicks EF, Rooijmans HG, van Gijn J. Outcome in conversion disorder: a follow up study. J Neurol Neurosurg Psychiatry 1995; 58: 750–2.
Cox DW, Prat L, Walshe JM, Heathcote J, Gaffney D. Twenty-four novel mutations in Wilson disease patients of predominantly European ancestry. Hum Mutat 2005; 26: 280.
Cree L, Samuels D, de Sousa Lopes S et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet 2008; 40: 249–54.
Crenna P, Carpinella I, Rabuffetti M et al. The association between impaired turning and normal straight walking in Parkinson's disease. Gait Posture 2007; 26: 172–8.
Crevits L, Versijpt J, Hanse M, De Ridder K. Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients. Neuropsychobiology 2000; 42(4): 202–6.
Crimlisk HL, Bhatia K, Cope H, David A, Marsden CD, Ron MA. Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ 1998; 316: 582–6.
Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol 1968; 18: 134–40.
Critchley EM, Nicholson JT, Betts JJ et al. Acanthocytosis, normolipoproteinaemia and multiple tics. Postgrad Med J 1970; 46: 698–701.
Critchley M. Arteriosclerotic parkinsonism. Brain 1929; 52(23): 833–83.
Crompton DE, Chinnery PF, Bates D et al. Spectrum of movement disorders in neuroferritinopathy. Mov Disord 2005; 20(1): 95–9.
Crone NE, Jinnah HA, Reich SG. Wilson's disease presenting with an unusual cough. Mov Disord 2005; 20: 891–3.
Crosby AH, Proukakis C. Is the transportation highway the right road for hereditary spastic paraplegia? Am J Hum Genet. 2002; 71: 1009–16.
Cuellar NG, Strumpf NE, Ratcliffe SJ. Symptoms of restless legs syndrome in older adults: outcomes on sleep quality, sleepiness, fatigue, depression, and quality of life. J Am Geriatr Soc 2007; 55(9): 1387–92.
Cullen TJ, Walker MA, Parkinson N et al. A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr Res 2003; 60: 157–66.
Cunningham MC, Maia DP, Teixeira AL Jr, Cardoso F. Sydenham's chorea is associated with decreased verbal fluency. Parkinsonism Relat Disord 2006; 12(3): 165–7.
Curless RG, Katz DA, Perryman RA, Ferrer PL, Gelblum J, Weiner WJ. Choreoathetosis after surgery for congenital heart disease. J Pediatr 1994; 124(5 Pt 1): 737–9.
Curtis AR, Fey C, Morris CM et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28(4): 350–4.
Curtis AR, Fey C, Morris CM et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28(4): 350–4.
Déjérine J, Roussy G. Le syndrome thalamique. Rev Neurol 1906; 14: 521–32.
Dabby R, Lange DJ, Trojaborg W, et al. Inclusion body myositis mimicking motor neuron disease. Arch Neurol 2001; 58: 1253–6.
Dagda RK, Merrill RA, Cribbs JT et al. The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory subunit Bbeta2 antagonizes neuronal survival by promoting mitochondrial fission. J Biol Chem 2008; 283(52): 36241–8.
Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson's disease Neuron 2009; 61(4): 502–10.
Dalakas M, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. A randomized controlled trial of high-dose intravenous immunoglobulin in the treatment of patients with stiff person syndrome. N Engl J Med 2001; 345: 1870–6.
Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody positive patients with stiff-person syndrome. Neurology 2000; 55: 1531–5.
Dalakas MC, Li M, Fujii M, Jacobowitz DM. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 2001; 57(5): 780–4.
Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 2009; 11(2): 102–10.
Dale RC, Church AJ, Cardoso F et al. Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol 2001; 50: 588–95.
Danek A, Dobson-Stone C, Velayos-Baeza A. The phenotype of chorea-acanthocytosis: a review of 106 patients with VPS13A mutations. Mov Disord 2005; 20: 1678.
Danek A, Rubio JP, Rampoldi L et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001; 50: 755–64.
Danek A, Walker RH. Neuroacanthocytosis. Curr Opin Neurol 2005; 18: 386–92.
Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341(7): 543–4.
Danos P, Schmidt A, Baumann B et al. Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study. Psychiatry Res 2005; 140: 281–9.
Das SK, Ray K. Wilson's disease: an update. Nat Clin Pract Neurol 2006; 2: 482–93.
Davies J, Tongroach P. Neuropharmacological studies on the nigro-striatal and raphe-striatal system in the rat. Eur J Pharmacol 1978; 51: 91–100.
Davison C. Pallido-pyramidal disease. J Neuropathol Exp Neurol 1954; 13: 50–9.
De Carvalho M, Swash, M. Cramps, muscle pain, and fasciculations: not always benign? Neurology 2004; 63: 721–3.
De Jong H. Action tremor in Parkinson's disease. J Nerv Ment Dis 1926; 64: 1.
de Jong LW, van der Hiele K, Veer IM et al. Strongly reduced volumes of putamen and thalamus in Alzheimer's disease: an MRI study. Brain 2008; 131: 3277–285.
De L, V, Morgante G, Musacchio MC et al. The safety of veralipride. Expert Opin Drug Saf 2006; 5: 695–701.
de Mello MT, Lauro FA, Silva AC, Tufik S. Incidence of periodic leg movements and of the restless legs syndrome during sleep following acute physical activity in spinal cord injury subjects. Spinal Cord 1996; 34(5): 294–6.
De Renzi E, Motti F, Nichelli P. Imitating gestures. A quantitative approach to ideomotor apraxia. Arch Neurol 1980; 37(1): 6–10.
DeCaria CM, Hollander E, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treamtent of pathological gambling. J Clin Psychiatry 1996; 57(Suppl 8): 80–83; discussion 83–4.
Dekker MC, Giesbergen PC, Njajou OT et al. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett 2003; 348(2): 117–9.
Delgado S, Baez S, Singer C et al. Parkinsonism/dystonia syndrome secondary to multiple sclerosis with antibasal ganglia antibodies. Mov Disord 2009; 24: 309–11.
Deliagina TG, Orlovsky GN. Comparative neurobiology of postural control. Curr Opin Neurobiol 2002; 12: 652–7.
Della Marca G, Vollono C, Mariotti P et al. Levetiracetam can be effective in the treatment of restless legs syndrome with periodic limb movements in sleep: report of two cases. J Neurol Neurosurg Psychiatry 2006; 77(4): 566–7.
DeLuca GC, Ebers GC, Esiri MM. The extent of axonal loss in the long tracts in hereditary spastic paraplegia. Neuropathol Appl Neurobiol 2004; 30: 576–84.
Demarquay G, Setiey A, Morel Y, Trepo C, Chazot G, Broussolle E. Clinical report of three patients with hereditary hemochromatosis and movement disorders. Mov Disord 2000; 15(6): 1204–9.
Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser–Fleischer rings. Neurology 1996; 46: 1040–3.
Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995; 38: 571–9.
Dening TR, Berrios GE, Walshe JM. Wilson's disease and epilepsy. Brain 1988; 111(Pt 5): 1139–55.
Dening TR. The neuropsychiatry of Wilson's disease: a review. Int J Psychiatry Med 1991; 21: 135–48.
Denny-Brown D. The nature of apraxia. J Nerv Ment Dis 1958; 126(1): 9–32.
DePold Hohler A, Ransom BR, Chun MR, Troster AI, Samii A. The youngest reported case of corticobasal degeneration. Parkinsonism Relat Disord 2003; 10(1): 47–50.
Deriu M, Cossu G, Molari A et al. Restless legs syndrome in multiple sclerosis: a case–control study. Mov Disord 2009; 24: 697–701.
Derry CP, Duncan JS, Berkovic SF. Paroxysmal motor disorders of sleep: the clinical spectrum and differentiation from epilepsy. Epilepsia 2006; 47: 1775.
Destee A, Bouchez P, Pellegrini P et al. Hemifacial spasm associated with a mixed benign parotid gland tumor. J Neurol Neurosurg Psychiatry 1985; 48: 189–90.
Dethy S, Luxen A, Bidaut LM, Goldman S. Hemibody tremor related to stroke. Stroke 199; 24(12): 2094–6.
Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998; 13(Suppl 3): 2–23.
Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998; 13(Suppl 3): 2–23.
Deuschl G, Blumberg H, Lücking CH. Tremor in reflex sympathetic dystrophy. Arch Neurol 1991; 48(12): 1247–52.
Deuschl G, Mischke G, Schenk E et al. Symptomatic and essential rhythmic palatal myoclonus. Brain 1990; 113: 1645–72.
Deuschl G, Wilms H, Krack P, Wurker M, Heiss WD: Function of the cerebellum in Parkinsonian rest tremor and Holmes' tremor. Ann Neurol 1999; 46: 126–8.
Deutschl G, Bain PG, Brin M and Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord 1998; 13: 2–23.
Deutschl G, Volkmann J, Raethjen J. Differential diagnosis, pathophysiology and therapy. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
Di Fonzo A, Dekker MC, Montagna P et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009; 72: 240–5.
Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, Esposito E. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 1998; 46: 547–54.
Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989; 87: 95–96.
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23(4): 394–400.
Dickson DW, Bergeron C, Chin SS et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61(11): 935–46.
Diederich NJ, Verhagen Metman L, Bakay RA, Alesch F. Ventral intermediate thalamic stimulation in complex tremor syndromes. Stereotact Funct Neurosurg 2008; 86: 167–72.
Dieterich M, Muller-Schunk S, Stephan T, Bense S, Seelos K, Yousry TA. Functional magnetic resonance imaging activations of cortical eye fields during saccades, smooth pursuit, and optokinetic nystagmus. Ann N Y Acad Sci 2009; 1164: 282–92.
Dietz V. Neurophysiology of gait disorders: present and future applications. Electroencephalogr Clin Neurophysiol 1997; 103: 333–55.
Digre K, Corbett JJ. Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol 1988; 49: 151–76.
Digree K, Corbett JA. Hemifacial spasm: differential diagnosis, mechanism and treatment. Adv Neurol 1988: 49: 151–76.
DiMauro S, Schon E. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008; 31: 91–123.
DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med, 2003; 348: 2656–68.
Djarmati A, Schneider SA, Lohmann K et al. Mutations in THAP1 (DYT6) are associated with generalised dystonia with prominent spasmodic dysphonia – a genetic screening study. Lancet Neurol 2009; 8: 447–52.
Dobson-Stone C, Danek A, Rampoldi L et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002; 10: 773–81.
Dobson-Stone C, Velayos-Baeza A, Filippone LA et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol 2004; 56: 299–302.
Dobson-Stone C, Velayos-Baeza A, Jansen A et al. Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. Neurogenetics 2005; 6: 151–8.
Dodel R, Spottke A, Gerhard A et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 2010; 25: 97–107.
Dohlinger S, Hauser TK, Borkert J, Luft AR, Schulz JB. Magnetic resonance imaging in spinocerebellar ataxias. Cerebellum 2008; 7(2): 204–14.
Donadi EA, Smith AG, Louzada-Junior P, Voltarelli JC, Nepom GT. HLA class I and class II profiles of patients presenting with Sydenham's chorea. J Neurol 2000; 247: 122–8.
Donofrio PD, Berger A, Brannagan TH 3rd et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions. Report of the AANEM ad hoc committee. Muscle Nerve 2009; 40(5): 890–900.
Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden–Spatz syndrome. Arch Neurol 1974; 30(1): 70–83.
Dray A, Davies J, Oakley NR et al. The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations. Brain Res 1978; 151: 431–42.
Drigo R, Fontana M, Coin A, Ferraresso A, Enzo E, Zambotto FM. APAP titration in patients with mild to moderate OSAS and periodic limb movement syndrome. Monaldi Arch Chest Dis 2006; 65(4): 196–203.
Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61(3): 422–3.
Driver-Dunckley ED, Noble BN, Hentz JG et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007; 30(5): 249–55.
Dubois B, Slachevsky A, Pillon B, Beato R, Villalponda JM, Litvan I. “Applause sign” helps to discriminate PSP from FTD and PD. Neurology 2005; 64(12): 2132–3.
Dubow JS, Panush SR, Rezak M et al. Acute dystonic reaction associated with foscarnet administration. Am J Ther 2008; 15: 184–6.
Duddy ME, Baker MR. Stiff person syndrome. Front Neurol Neurosci 2009; 26: 147–65.
Duenas AM, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain 2006; 129(Pt 6): 1357–70.
Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000; 54(8): 1698–700.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255–9.
Edwards M, Wood N, Bhatia K. Unusual phenotypes in DYT1 dystonia: a report of five cases and a review of the literature. Mov Disord 2003; 18: 706–11.
EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992; 15(2): 173–84.
Egan RA, Weleber RG, Hogarth P et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden–Spatz syndrome). Am J Ophthalmol 2005; 140(2): 267–74.
Eggert T. Eye movement recordings: methods. Dev Ophthalmol 2007; 40: 15–34.
Ehni G,Woltman HW. Hemifacial spasm. Arch Neurol Psychiatry 1945; 53: 205–11.
Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16: 1176–7.
Eidelberg D, Dhawan V, Moeller JR et al. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991; 54(10): 856–62.
Eisen JL, Leonard HL, Swedo SE et al. The use of antibody D8/17 to identify B cells in adults with obsessive-compulsive disorder. Psychiatry Res 2001; 104: 221–5.
Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 2004; 251(5): 579–83.
Eisensehr I, Wetter TC, Linke R et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57(7): 1307–9.
Ekbom KA. Restless legs syndrome. Acta Med Scand 1945; 158(Suppl.): 4–124.
El Fakhri G, Habert MO, Maksud P et al. Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2006; 33: 87–92.
El-Youssef M. Wilson disease. Mayo Clin Proc 2003; 78: 1126–36.
Elble RJ, Moody C, Leffler K, Sinha R. The initiation of normal walking. Mov Dis 1994; 9: 139–46.
Elble RJ, Thomas SS, Higgins C, Colliver J. Stride-dependent changes in gait of older people. J Neurol 1991; 238: 1–5.
Elble RJ. Tremor: clinical features, pathophysiology, and treatment. Neurol Clin 2009; 27(3): 679–95.
Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm 2005; 112: 991–1003.
Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm 2001; 108: 909–23.
Ellingsen DG, Bast-Pettersen R, Efskind J et al. Hand tremor related to smoking habits and the consumption of caffeine in male industrial workers. Neurotoxicology 2006; 27(4): 525–33.
Ellis RJ. Tremor and movement disorders after whiplash type injuries. J Neurol Neurosurg Psychiatry 1997; 87: 1884–6.
Ellis SJ. Tremor and other movement disorders after whiplash type injuries. J Neurol Neurosurg Psychiatry 1997; 63(1): 110–12.
Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509–18.
Engel J, Pedley TA. In: Epilepsy: A Comprehensive Textbook. 2nd ed. Alphen aan den Rijn: Wolters Kluwer; 2008: Chapters 44, 49.
Enomoto M, Inoue Y, Namba K, Munezawa T, Matsuura M. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients. Mov Disord 2008; 23(6): 811–6; quiz 926.
Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol 2000; 247: 787–92.
Ertan S, Uluduz D, Ozekmekçi S et al. Clinical characteristics of 49 patients with psychogenic movement disorders in a tertiary clinic in Turkey. Mov Disord 2009; 24: 759–62.
Ertan S, Uluduz D, Ozekmekci S et al. Clinical characteristics of 49 patients with psychogenic movement disorders in a tertiary clinic in Turkey. Mov Disord 2009; 24: 759–62.
Espay AJ, Bergeron C, Chen R et al. Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. Mov Disord 2006; 21: 2251–4.
Espay AJ, Goldenhar LM, Voon V, Schrag A, Burton N, Lang AE. Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: an international survey of movement disorder society members. Mov Disord 2009; 24: 1366–74.
Espay AJ, Morgante F, Purzner J, Gunraj CA, Lang AE, Chen R. Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol 2006; 59: 825–34.
Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008; 23: 401–4.
Estorch M, Camacho V, Paredes P et al. Cardiac I-123-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008; 35: 1636–41.
Evans AH, Katzenschlager R, Paviour D et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19(4): 397–405.
Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65(10): 1570–4.
Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004; 17(4): 393–8.
Ezpeleta D, de Andrés C, Giménez-Roldán S. Abnormal movements in a case of extrapontine myelinolysis. Review of the literature. Rev Neurol 1998; 26: 215–20.
Fabiani G, Teive HA, Sá D et al. Palatal myoclonus: report of two cases. Arq Neuropsiquiatr 2000; 58(3B): 901–4.
Fahn S, Jankovic J. Principles and Practices of Movement Disorders. Philadelphia: Elsiever; 2007: 519–40.
Fahn S, Williams DT. Psychogenic dystonia. Adv Neurol 1988; 50: 431–55.
Fahn S, Williams DT. Psychogenic dystonia. In: Fahn S, Marsden CD, Calne DB, eds. Dystonia 2. New York: Raven Press; 1988: 431–55.
Fahn S. Concept and classification of dystonia. Adv Neurol 1988; 50: 1–8.
Fahn S. The paroxysmal dyskinesias. In: Marsden CD, Fahn S, eds. Movement Disorders. Oxford: Butterworth Heinmann; 1994: 310–45.
Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47: S2–S9.
Fearing MA, Bigler ED, Wilde EA et al. Morphometric MRI findings in the thalamus and brainstem in children after moderate to severe traumatic brain injury. J Child Neurol 2008; 23: 729–37.
Federico A, Battistini S, Ciacci G et al. Cherry-red spot myoclonus syndrome (type I sialidosis). Dev Neurosci 1991; 13(4–5): 320–6.
Feekes JA, Cassell MD. The vascular supply of the functional compartments of the human striatum. Brain 2006; 129(8): 2189–201. doi: 10.1093/brain/awl158.
Feigin A, Tang C, Ma Y et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007; 130: 2858–67.
Feldman BM, Zabriskie JB, Silverman ED, Laxer RM. Diagnostic use of B-cell alloantigen D8/17 in rheumatic chorea. J Pediatr 1993; 123: 84–6.
Ferenci P, Caca K, Loudianos G et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23: 139–42.
Ferenci P, Steindl-Munda P, Vogel W et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease. Clin Gastroenterol Hepatol 2005; 3: 811–8.
Ferini-Strambi L, Bonati MT, Oldani A, Aridon P, Zucconi M, Casari G. Genetics in restless legs syndrome. Sleep Med 2004; 5(3): 301–4.
Ferlazzo E, Morgante F, Rizzo V et al. Successful treatment of Holmes tremor by levetiracetam. Mov Disord 2008: 23(14): 2101–3.
Ferman TJ, Smith GE, Boeve BF et al. DLB fluctuations – Specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62: 181–7.
Fernández Cooke E, Simón de Las Heras R, Muñoz González A, Allende Martinez L, Camacho Salas A. Choreoathetosis after Herpes simplex encephalitis. An Pediatr (Barc.) 2009; 71: 153–6.
Fernandez Gonzalez F, Seijo F, Salvador C et al. Applied neurophysiology in the deep brain stimulation treatment of multiple sclerosis tremor. Rev Neurol 2001; 32: 559–67.
Fernandez HH, Durso R. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord 1998; 13(3): 597–8.
Fernandez HH, Friedman JH. Punding on l-dopa. Mov Disord 1999; 14(5): 836–8.
Fernandez HH, Nguyen FN, Shapiro MA, Cooper C, Wood MF, Okun MS. Compulsive behavior versus impulse control disorders: a single-center experience from the University of Florida Movement Disorders Center. Mov Disord 2008; 23(9): 1335–6.
Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513–5.
Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol 2009; 256(3): 320–2.
Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. Paediatr Drugs 2009; 11(5): 293–307.
Ferraz HB, Andrade LA. Symptomatic dystonia: clinical profile of 46 Brazilian patients. Can J Neurol Sci 1992; 19: 504–507.
Ferreirinha F, Quattrini A, Pirozzi M et al. Axonal degeneration in paraplegin deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J Clin Invest 2004; 113: 231–42.
Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2002; 104(6): 583–91.
Ferri R, Lanuzza B, Cosentino FI et al. A single question for the rapid screening of restless legs syndrome in the neurological clinical practice. Eur J Neurol 2007; 14(9): 1016–21.
Ferrrara JM, Stacy M. Impulse-control disorders in Parkinson's disease. CNS Spectr 2008; 13(8): 690–8.
Feys P, Helsen W, Liu X et al. Effects of peripheral cooling on intention tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76: 373–9.
Feys P, Maes F, Nuttin B et al. Relationship between multiple sclerosis intention tremor severity and lesion load in the brainstem. Neuroreport 2005; 16: 1379–82.
Fife TD, Baloh RW. Disequilibrium of unknown cause in older people. Ann Neurol 1993; 34: 694–702.
Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998; 9: 703–7.
Fink JK, Hedera P. Hereditary spastic paraplegia: genetic heterogeneity and genotype-phenotype correlation. Semin Neurol 1999; 19: 301–9.
Fink JK. Advances in hereditary spastic paraplegia. Curr Opin Neurol 1997; 10: 313–8.
Fink JK. Advances in hereditary spastic paraplegias. Exp Neurol 2003; 184: 106–10.
Fink JK. Hereditary spastic paraplegia. Neurol Clin 2002; 20: 711–726.
Fink JK. The hereditary spastic paraplegias: nine genes and counting. Arch Neurol 2003; 60: 1045–9.
Finsterer J, Muellbacher W, Mamoli B. Yes/yes head tremor without appendicular tremor after bilateral cerebellar infarction. J Neurol Sci 1996; 139(2): 242–5.
Finsterer J. Ataxias with autosomal, X-chromosomal or maternal inheritance. Can J Neurol Sci 2009; 36(4): 409–28.
Finsterer J. Mitochondrial disorders, cognitive impairment and dementia. J Neurol Sci 2009; 283: 143–8.
Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol 14: 29–44.
Fishman PS. Paradoxical aspects of parkinsonian tremor. Mov Disord 2008; 168–73.
Fitzgerald DB, Drago V, Jeong Y, Chang YL, White KD, Heilman KM. Asymmetrical alien hands in corticobasal degeneration. Mov Disord 2007; 22(4): 581–4.
FitzGerald PM, Jankovic J. Orthostatic tremor: An association with essential tremor. Mov Disord 1991; 6: 60.
Fleet WS, Watson RT. From benign fasciculations and cramps to motor neuron disease. Neurology 1986; 36: 997–8.
Floris-Moore MA, Amodio-Groton MI, Catalano MT. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother 2003; 37(12): 1810–3.
Fogel BL, Perlman S. An approach to the patient with late-onset cerebellar ataxia. Nat Clin Pract Neurol 2006; 2(11): 629–35; quiz 1 p following 35.
Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol 2007; 6(3): 245–57.
Fogel BL, Salamon N, Perlman S. Progressive spinocerebellar ataxia mimicked by a presumptive cerebellar arteriovenous malformation. Eur J Radiol Extra 2009; 71(1): e1–e2.
Fontenelle LF, Leite MA. Treatment-resistant self-mutilation, tics, and obsessive-compulsive disorder in neuroacanthocytosis: a mouth guard as a therapeutic approach. J Clin Psychiatry 2008; 69: 1186–7.
Foote KD et al. Use of two DBS electrodes to treat post-traumatic tremor. NIH K23 NS052557–01. datalab-1.ics.uci.edu/nih/crisp/2007/getdoc.php?did=55670 (accessed December 23, 2010).
Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008; 23(6): 904–7.
Foubert-Samier A, Kazadi A, Rouanet M et al. Axonal sensory motor neuropathy in copper-deficient Wilson's disease. Muscle Nerve 2009; 40: 294–6.
Fox GC, Ebeid S, Vincenti G. Paroxetine-induced chorea. Br J Psychiatry 1997; 170: 193–4.
Fragoso YD, Araujo MG, Branco NL. Kinesigenic paroxysmal hemidyskinesia as the initial presentation of multiple sclerosis. MedGenMed 2006; 8: 3.
Franca MC, D'Abreu A, Maurer-Morlli CV et al. Prospective neuroimaging study in hereditary spastic paraplegia with thin corpus callosum. Mov Disord 2007; 22: 1556–62.
Frattali CM, Sonies BC. Speech and swallowing disturbances in corticobasal degeneration. Adv Neurol 2000; 82: 153–60.
Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S. Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 2007; 51(Pt 6): 417–26.
Friedman J, Lannon M, Comella C et al. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757–63.
Friedman J, Standaert DG. Neurogenetics of dystonia and paroxysmal dyskinesias. Neurogenetics: Scientific and Clinical Advances. New York: Marcel Dekker; 2005: 403–26.
Friess E, Kuempfel T, Modell S et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 2006; 12: 432–7.
Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, Balcer LJ. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008; 4(12): 664–75.
Frucht S, Bordelon Y, Houghton WH. Marked amelioration of alcohol-responsive posthypoxic myoclonus by gamma-hydroxybutyric acid (Xyrem). Mov Disord 2005; 20: 745–51.
Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000; 15(2): 340–3.
Frucht S, Louis E, Chuang C et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001; 57: 1112–14.
Frucht S, Sun D, Schiff N, Eidelberg D, Gilliam TC. Arm tremor secondary to Wilson's disease. Mov Disord 1998; 13(2): 351–3.
Fuchs T, Gavarini S, Saunders-Pullman R et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009; 41: 286–8.
Fujishiro H, Ferman TJ, Boeve BF et al. Validation of the neuropathologic criteria of the Third Consortium for Dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008; 67: 649–56.
Fukui T, Hasegawa Y, Seriyama S, Takeuchi T, Sugita K, Tsukagoshi H. Hemiballism-hemichorea induced by subcortical ischemia. Can J Neurol Sci 1993; 20(4): 324–8.
Fung GP, Chan KY. Cervical myelopathy in an adolescent with Hallervorden–Spatz disease. Pediatr Neurol 2003; 29(4): 337–40.
Furiya Y, Hirano M, Kurumatani N et al. Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 2005; 138: 178–81.
Furukawa Y, Guttman M, Sparagana SP et al. Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. Ann Neurol 2000; 47: 517–20.
Galili R, Mosberg, Gil-Ad I et al. Haloperidol-induced neurotoxicity – possible implications for tardive dyskinesia. J Neural Transm 2000; 107: 479–90.
Gallyas F, Wolff JR. Metal-catalyzed oxidation renders silver intensification selective. Applications for the histochemistry of diaminobenzidine and neurofibrillary changes. J Histochem Cytochem 1986; 34: 1667–72.
Galvez-Jimenez N, Lang AE. Psychogenic movement disorders. In: Watt RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. New York: McGraw-Hill; 1997: 715–32.
Galvez-Jimenez, Nestor, M.D, Hanson, Maurice, M.D., Desai, Mehul, M.D. Unusual causes of hemifacial spasm. Seminars in Neurology 2001. 21: 75–83.
Gandhi S, Hardie RJ, Lees AJ. An update on the Hardie neuroacanthocytosis series. In: Walker RH, Saiki S, Danek A, eds. Neuroacanthocytosis Syndromes II. Berlin, Heidelberg: Springer-Verlag; 2008: 43–51.
Gandon J, Trotoux J, Peghegre R et al. Bilan de 158 parotidectomies et problèmes histologiques poses par le tumeurs mixtes des glandes salivaires. Ann Otolaryngol (Paris) 1979; 96: 261–80.
Garbutt S, Matlin A, Hellmuth J et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain 2008; 131(Pt 5): 1268–81.
Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004; 75(10): 1386–94.
Garcia-Borreguero D, Allen RP, Benes H et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007; 22(Suppl 18): S476–84.
Garcia-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006; 10(3): 153–67.
Garcia-Borreguero D, Kohnen R, Hogl B et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007; 8(5): 455–63.
Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59(10): 1573–9.
Garcia-Cazorla A, Rabier D, Touati G et al. Pyruvate carboxylase deficiency: metabolic characteristics and new neurological aspects. Ann Neurol 2006; 59: 121–7.
Garcia-Ruiz P. Calcium channel blocker-induced parkinsonism: clinical features and comparison with Parkinson's disease. Parkinsonism Relat Disord 1998; 4(4): 211–14.
Garcia-Ruiz PJ, Garcia de YJ, Jimenez-Jimenez FJ et al. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 1992; 15: 19–26.
Gardner WT, Sava GA. Hemifacial spasm: a reversible pathophysiologic state. J Neurosurg 962; 19: 240–7.
Gareri P, De FP, De FS et al. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006; 23: 937–56.
Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005; 20: 424–9.
Gasser T, Windgassen K, Bereznai B et al. Phenotypic expression of the DYT1 mutation: a family with writer's cramp of juvenile onset. Ann Neurol 1998; 44: 126–28.
Gebhardt A, Vanbellingen T, Baronti F et al. Poor dopaminergic response of impaired dexterity in Parkinson's disease: bradykinesia or limb kinetic apraxia? Mov Disord 2008; 23(12): 1701–6.
Geis C, Beck M, Jablonka S et al. Stiff person syndrome associated anti-amphiphysin antibodies reduce GABA associated [Ca2+]i rise in embryonic motor neurons. Neurobiol Dis 2009; 36: 191–9.
Gemignani F, Brindani F, Vitetta F, Marbini A, Calzetti S. Restless legs syndrome in diabetic neuropathy: a frequent manifestation of small fiber neuropathy. J Peripher Nerv Syst 2007; 12(1): 50–3.
Gemignani F, Marbini A, Di Giovanni G et al. Cryoglobulinaemic neuropathy manifesting with restless legs syndrome. J Neurol Sci 1997; 152(2): 218–23.
Gemignani F, Marbini A. Restless legs syndrome and peripheral neuropathy. J Neurol Neurosurg Psychiatry 2002; 72(4): 555.
Gemignani F. A further cause of secondary restless legs syndrome: Crohn's disease. Inflamm Bowel Dis 2010; 16(2): 280–1.
Genes D, Rechart W, Fernandez-Real JM et al. Hemifacial spasm and hypothyroidism. Lancet 1993; 342: 1112.
George G. Case Report: Hypothyroidism presenting as puzzling myalgias and cramps in 3 patients. J Clin Rheumatol 2007; 13: 273–5.
Gerhard A, Watts J, Trender-Gerhard I et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 2004; 19(10): 1221–6.
Gerschlager W, Brown P. Myoclonus. Curr Opin Neurol 2009; 22: 414–18.
Gerschlager W, Münchau A, Katzenschlager R et al. Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord 2004; 19(7): 788–95.
Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 1994; 5: 127–32.
Gershanik OS. Stiff-person syndrome. Parkinsonism Relat Disord 2009: 15(Suppl 3): S130–S134.
Gervais-Bernard H, Xie-Brustolin J, Mertens P et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol 2009; 256(2): 225–33.
Geschwind N, Kaplan E. A human cerebral deconnection syndrome. A preliminary report. Neurology 1962; 12: 675–85.
Geschwind N. The apraxias: neural mechanisms of disorders of learned movement. Am Sci 1975; 63(2): 188–95.
Geser F, Tolnay M, Jung HH. The Neuropathology of McLeod Syndrome. In: Walker RH, Saiki S, Danek A, eds. Neuroacanthocytosis Syndromes II. Berlin, Heidelberg: Springer-Verlag; 2008: 197–203.
Geser F, Wenning GK, Seppi K et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006; 21: 179–86.
Ghaffar O, Staines WR, Feinstein A. Unexplained neurologic symptoms: an fMRI study of sensory conversion disorder. Neurology 2006; 67: 2036–8.
Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991; 41(7): 986–91.
Ghika J. Bogousslavsky J. Abnormal Movements. Stroke Syndromes. 2nd ed. Cambridge: Cambridge University Press; 2001; 162–81.
Ghika-Schmid F, Ghika J, Regli F, Bogousslavsky J. Hyperkinetic movement disorders during and after acute stroke: The Lausanne Stroke Registry. J Neurol Sci 1997; 146(2): 109–16.
Ghika-Schmid F, Ghika J, Regli F, Bogousslavsky J. Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry. J Neurol Sci 1997; 146: 109–16.
Ghorayeb I, Bioulac B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm 2005; 112: 1669–75.
Giagheddu M, Tamburini G, Piga M et al. Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease. Acta Neurol Scand 2001; 103: 71–81.
Gibb WR, Lees AJ, Marsden CD. Pathological report of four patients presenting with cranial dystonias. Mov Disord 1988; 3: 211–21.
Gibson JM, Kennard C. Quantitative study of “on-off” fluctuations in the ocular motor system in Parkinson's disease. Adv Neurol 1987; 45: 329–33.
Gidding SS, Lichtenstein AH, Faith MS et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009; 119(8): 1161–75.
Giedd JN, Rapoport JL, Kruesi MJ et al. Sydenham's chorea: magnetic resonance imaging of the basal ganglia. Neurology 1995; 45: 2199–202.
Giladi N, McDermott MP, Fahn S et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56: 1712–21.
Giladi N, Treves TA, Simon ES et al. Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm 2001; 108: 53–61.
Gilbert DL, Christian BT, Gelfand MJ, Shi B, Mantil J, Sallee FR. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 2006; 67(9): 1695–7.
Gille M, Jacquemin C, Kiame G et al. Central pontine myelinolysis with cerebellar ataxia and dystonia. Rev Neurol (Paris) 1993; 149: 344–6.
Gilman S, Low P, Quinn N et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8: 359–62.
Gilman S, May SJ, Shults CW et al. The North American Multiple System Atrophy Study Group. J Neural Transm 2005; 112: 1687–94.
Gilman S, Sima AA, Junck L et al. Spinocerebellar ataxia type 1 with multiple system degeneration and glial cytoplasmic inclusions. Ann Neurol 1996; 39: 241–55.
Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–6.
Gilman S, Wenning GK, Low PA JQ et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71(9): 670–6.
Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68(4): 423–8.
Gitiaux C, Roze E, Kinugawa K et al. Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patients. Mov Disord 2008; 23(16): 2392–7.
Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive function in lewy body dementia: comparison with Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry 1997; 62: 243–52.
Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985; 35: 749–51.
Goetz CG, Tanner CM, Stebbins GT, Leipzig G, Carr WC. Adult tics in Gilles de la Tourette's syndrome: description and risk factors. Neurology 1992; 42: 784–8.
Goizet C, Boukhris A, Durr A et al. CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5. Brain 2009; 132: 1589–600.
Goizet C, Boukhris A, Maltete D et al. SPG15 is the second most common cause of hereditary spastic paraplegia with thin corpus callosum. Neurology 2009; 73: 1111–9.
Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130(Pt 6): 1552–65.
Goldenberg G, Wimmer A, Auff E et al. Impairment of motor planning in patients with Parkinson's disease: evidence from ideomotor apraxia testing. J Neurol Neurosurg Psychiatry 1986; 49(11): 1266–72.
Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008; 23: 2248–50.
Goldman S, Ahlskog JE. Posttraumatic cervical dystonia. Mayo Clin Proc 1993; 68: 443–8.
Goldman S, Amrom D, Szliwowski HB et al. Reversible striatal hypermetabolism in a case of Sydenham's chorea. Mov Disord 1993; 8: 355–8.
Goldstein JE, Cogan DG. Apraxia of lid opening. Arch Ophthalmol 1965; 73: 155–9.
Gomperts SN, Rentz DM, Moran E et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903–10.
Gong G, Concha L, Beaulieu C et al. Thalamic diffusion and volumetry in temporal lobe epilepsy with and without mesial temporal sclerosis. Epilepsy Res 2008; 80: 184–93.
Gonzalez-Alegre P, Ammache Z, Davis PH, Rodnitzky RL. Moyamoya-induced paroxysmal dyskinesia. Mov Disord 2003; 18: 1051–6.
Gonzalez-Alegre P. Monomelic parkinsonian tremor caused by contralateral substantia nigra stroke. Parkinsonism Relat Disord 2007; 13(3): 182–4.
Goodman JD, Brodie C, Ayida GA. Restless leg syndrome in pregnancy. BMJ 1988; 297(6656): 1101–2.
Gordon EE, Januszko DM, Kaufman L. A critical survey of stiff-man syndrome. Am J Med 1967; 42: 582–99.
Gowers WR. A Manual of Disease of the Nervous System. Vol 2. Darien, CT: Hafner; 1970: 248–59.
Goytain A, Hines RM, El-Husseini A et al. NIPA1 (SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg transporter. J Biol Chem 2007; 282(11): 8060–8.
Grünthal E. Über thalamische Demenz. Monatsschr Psychiatr Neurol 1942; 106: 114–28.
Grabowski M, Zimprich A, Lorenz-Depiereux B et al. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 2003; 11: 138–44.
Gradstein L, Danek A, Grafman J, Fitzgibbon EJ. Eye movements in chorea-acanthocytosis. Invest Ophthalmol Vis Sci 2005; 46(6): 1979–87.
Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969; 32: 28–34.
Graham NL, Bak T, Patterson K, Hodges JR. Language function and dysfunction in corticobasal degeneration. Neurology 2003; 61(4): 493–9.
Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003; 18(11): 1224–32.
Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24: 1715–14.
Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24: 1715–24.
Gray F, Eizenbaum JF, Gherardi R et al. Luyso-pallido-nigral atrophy and amyotrophic lateral sclerosis. Acta Neuropathol 1985; 66: 78–82.
Graziewicz M, Longley M, Copeland W. DNA polymerase gamma in mitochondrial DNA replication and repair. Chem Rev 2006; 106: 383–405.
Green P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord 1995; 10: 143–52.
Green RC, Roberts JS, Cupples LA et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009; 361(3): 245–54.
Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992; 15: 276–88.
Gregory A, Hayflick SJ. Panthothenate kinase-associated neurodegeneration. Available at: www.genetests.org. Initial Posting: August 13, 2002; Last Update: March 23, 2010. (Accessed January 3, 2011).
Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009; 46(2): 73–80.
Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet. 2009; 46(2): 73–80.
Gregory A, Westaway SK, Holm IE et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71(18): 1402–9.
Grimaldi LM, Martino G, Braghi S et al. Heterogeneity of autoantibodies in stiff man syndrome. Ann Neurol 1993; 34: 57–64.
Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord 2008; 23: 970–6.
Grimes DA, Han F, Lang AE et al. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology 2002; 59: 1183–6.
Grimes DA, Lang AE, Bergeron C. Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry 2000; 69(3): 392–5.
Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53(9): 1969–74.
Gromadzka G, Schmidt HH, Genschel J et al. Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease. Clin Genet 2005; 68: 524–32.
Gros-Louis F, Dupre N, Dion P et al. Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia. Nat Genet 2007; 39(1): 80–5.
Grossman M, McMillan C, Moore P et al. What's in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer's disease, frontotemporal dementia and corticobasal degeneration. Brain 2004; 127(Pt 3): 628–49.
Grotzsch H, Pizzolato GP, Ghika J et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology 2002; 58: 1839–42.
Grunewald A, Djarmati A, Lohmann-Hedrich K et al. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 2008; 29: 331–2.
Guay DR. Clinical Review: Are there alternatives to the use of quinine to treat nocturnal leg cramps? Consult Pharm 2008; 23: 141–56.
Gubitz AK, Gwinn K. Mining the genome for susceptibility to complex neurological disorders. Curr Mol Med 2009; 9(7): 801–13.
Guidelines for diagnosis of rheumatic fever, Jones criteria, 1992 update. Special Writing Group of the Committee of Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardio-Vascular Disease of the Young of the American Heart Association. Guidelines for the diagnosis of rheumatic fever. JAMA 1992; 268: 2069–73.
Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol 2009; 22: 430–6.
Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol 2009; 22: 430–6.
Hälbig TD, Tse W, Frisina PG et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009; 16(4): 493–7.
Haas R, Dietrich R. Neuroimaging of mitochondrial disorders. Mitochondrion 2004; 4: 471–90.
Haba-Rubio J, Staner L, Petiau C, Erb G, Schunck T, Macher JP. Restless legs syndrome and low brain iron levels in patients with haemochromatosis. J Neurol Neurosurg Psychiatry 2005; 76(7): 1009–10.
Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23(Suppl 1): 15–26.
Hadjivassiliou M, Boscolo S, Tongiorgi E et al. Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 2008; 23(10): 1370–7.
Haik S, Galanaud D, Linguraru MG et al. In vivo detection of thalamic gliosis: a pathoradiologic demonstration in familial fatal insomnia. Arch Neurol 2008; 65: 545–9.
Haile CN, Kosten TR, Kosten TA. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse 2009; 35(3): 161–77.
Hakonen AH, Goffart S, Marjavaara S et al. Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. Hum Mol Genet 2008; 17(23): 3822–35.
Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392–9.
Hall DA, Berry-Kravis E, Jacquemont S et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005; 65(2): 299–301.
Hall M. On Diseases and Derangements of the Nervous System in Their Primary Forms and in Their Modifications by Age, Sex, Constitution, Hereditary Predisposition, Excesses, General Disorder and Organic Disease. London: Balliére; 1841.
Hallet M, Chadwich D, Adam J, Marsden CD. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry 1977a; 40: 253–64.
Hallet M, Lindsey J, Adelstein B, Riley P. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 1985; 35: 1374–7.
Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 2005; 128: 2272–80.
Halliday W. The nosology of Hallervorden–Spatz disease. J Neurol Sci 1995; 134(Suppl): 84–91.
Halligan PW, Athwal BS, Oakley DA, Frackowiak RS. Imaging hypnotic paralysis: implications for conversion hysteria. Lancet 2000; 355: 986–7.
Hamilton JM, Haaland KY, Adair JC et al. Ideomotor limb apraxia in Huntington's disease: implications for corticostriate involvement. Neuropsychologia 2003; 41(5): 614–21.
Hamilton SR. Neuro-ophthalmology of movement disorders. Curr Opin Ophthalmol 2000; 11(6): 403–7.
Handley A, Medcalf P, Hellier K, Dutta D. Movement disorders after stroke. Age Ageing 2009; 38: 260–6.
Hanein S, Martin E, Boukhris A et al. Identification of the SPG15 gene, encoding Spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet 2008; 82: 992–1002.
Hanna PA, Kumar S, Walters AS. Restless legs symptoms in a patient with above knee amputations: a case of phantom restless legs. Clin Neuropharmacol 2004; 27(2): 87–9.
Hanson M, Honour M, Singleton A, Crawley A, Hardy J, Gwinn-Hardy K. Analysis of familial and sporadic restless legs syndrome in age of onset, gender, and severity features. J Neurol 2004; 251(11): 1398–401.
Hanukoglu A, Curiel B, Berkowitz D, Levine A, Sack J, Lorberboym M. Hypothyroidism and dyshormonogenesis induced by d-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease. J Pediatr 2008; 153: 864–6.
Happe S, Vennemann M, Evers S, Berger K. Treatment of individuals with known and unknown restless legs syndrome in the community. J Neurol 2008; 255(9): 1365–71.
Hara K, Momose Y, Tokiguchi S et al. Multiplex families with multiple system atrophy. Arch Neurol 2007; 64: 545–51.
Harder A, Jendroska K, Kreuz F et al. Novel twelve-generation kindred of fatal familial insomnia from Germany representing the entire spectrum of disease expression. Am J Med Genet 1999; 87: 11–16.
Hardie RJ, Pullon HW, Harding AE et al. Brain 1991; 114: 13–49.
Hardie RJ, Pullon HW, Harding AE et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991; 114: 13–49.
Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet 1983; 1(8334): 1151–5.
Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet 1983; 1(8334): 1151–5.
Harding AE. Hereditary “pure” spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry 1981; 44(10): 871–83.
Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391–403.
Harel L, Zeharia A, Kodman Y et al. Presence of the d8/17 B-cell marker in children with rheumatic fever in Israel. Clin Genet 2002; 61: 293–8.
Harris CM, Shawkat F, Russell-Eggitt I et al. Intermittent horizontal saccade failure (‘ocular motor apraxia’) in children. Br J Ophthalmol 1996; 80(2): 151–8.
Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995; 92(7): 2539–43.
Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993; 8: 19–27.
Hartig MB, Hortnagel K, Garavaglia B et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006; 59(2): 248–56.
Hattan E, Angle MR, Chalk C. Unexpected benefit of propofol in stiff-person syndrome. Neurology 2008; 70: 1641–2.
Hauser TK, Luft A, Skalej M et al. Visualization and quantification of disease progression in multiple system atrophy. Mov Disord 2006; 21: 1674–81.
Hauw JJ, Daniel SE, Dickson D et al. Preliminary NINDS neuropathologic criteria for Steele–Richardson–Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44(11): 2015–19.
Haverfield EV, Dempsey MA, Gregory A, Westaway SK, Hayflick SJ, Das S. Intragenic deletion and duplication analysis of PANK2 and PLA2G6 genes in patients with NBIA. ACMG Annual Clinical Genetics Meeting 2008. Abstract Number:150.
Hayashi A, Nakamagoe K, Ohkoshi N, Hoshino S, Shoji S. Double filtration plasma exchange and immunoadsorption therapy in a case of stiff-man syndrome with negative anti-GAD antibody. J Med 1999; 30(5–6): 321–7.
Haydardedeoglu FE, Tutkak H, Kose K, Duzgun N. Genetic susceptibility to rheumatic heart disease and streptococcal pharyngitis: association with HLA-DR alleles. Tissue Antigens 2006; 68: 293–6.
Hayes MW, Graham S, Heldorf P, de Moore G, Morris JG. A video review of the diagnosis of psychogenic gait: appendix and commentary. Mov Disord 1999; 14: 914–21.
Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. Am J Neuroradiol 2006; 27(6): 1230–3.
Hayflick SJ, Penzien JM, Michl W, Sharif UM, Rosman NP, Wheeler PG. Cranial MRI changes may precede symptoms in Hallervorden–Spatz syndrome. Pediatr Neurol 2001; 25(2): 166–169.
Hayflick SJ, Westaway SK, Levinson B et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med 2003; 348(1): 33–40.
Hayflick SJ, Westaway SK, Levinson B et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med 2003; 348: 33–40.
Hayflick SJ. Unraveling the Hallervorden–Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003; 15(6): 572–7.
Hayflick SJ. Unraveling the Hallervorden–Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003; 15(6): 572–7.
Hayflick SJ. Unraveling the Hallervorden–Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003; 15(6): 572–7.
Head RA, de Goede CG, Newton RW et al. Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Dev Med Child Neurol 2004; 46(10): 710–2.
Hecht MJ, Stolze H, Auf dem Brinke M et al. Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia: report of 19 cases. Mov Disord 2008; 23: 228–33.
Hedera P, Brewer GJ, Fink JK. White matter changes in Wilson disease. Arch Neurol 2002; 59: 866–7.
Hedera P, Eldevik OP, Maly P et al. Spinal cord magnetic resonance imaging in autosomal dominant hereditary spastic paraplegia. Neuroradiology 2005; 47: 730–4.
Hedrich K, Meyer EM, Schule B et al. Myoclonus-dystonia: detection of novel, recurrent, and de novo SGCE mutations. Neurology 2004; 62: 1229–31.
Heilman K, Rothi LJG. Apraxia. In: Heilman K, Valenstein, E eds. Clinical Neuropsychology. 2nd ed. New York: Oxford University Press; 1985: 131–50.
Heilman KM, Maher LM, Greenwald ML et al. Conceptual apraxia from lateralized lesions. Neurology 1997; 49(2): 457–64.
Heilman KM, Rothi LJ, Valenstein E. Two forms of ideomotor apraxia. Neurology 1982; 32(4): 342–6.
Heinz A, Wohrle J, Schols L, Klotz P, Kuhn W, Przuntek H. Continuous subcutaneous lisuride infusion in OPCA. J Neural Transm Gen Sect 1992; 90: 145–50.
Hellenbroich Y, Bernard V, Zuhlke C. Spinocerebellar ataxia type 4 and 16q22.1-linked Japanese ataxia are not allelic. J Neurol 2008; 255(4): 612–3.
Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600–9.
Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004; 5(3): 237–46.
Hening WA. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007; 120(1 Suppl 1): S22–7.
Henkel K, Danek A, Grafman J et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: a voxel-based morphometry study. Mov Disord 2006; 21: 1728–31.
Henry RG, Shieh M, Amirbekian B et al. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009; 282: 61–6.
Hewamadduma C, McDermott CJ, Kirby J et al. New pedigrees and novel mutations expand the phenotype of REEP1-associated hereditary spastic paraplegia. Neurogenetics 2009; 10: 105–10.
Hewer E, Danek A, Schoser BG et al. McLeod myopathy revisited: more neurogenic and less benign. Brain 2007; 130: 3285–96.
HGNC Database. HUGO Gene Nomenclature Committee (HGNC), EMBL Outstation – Hinxton, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK. www.genenames.org.
Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, Adler RL. An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy. Neurology 2000; 55(9): 1364–7.
Higgins JJ, Pho LT, Ide SE, Nee LE, Polymeropoulos MH. Evidence for a new spinocerebellar ataxia locus. Mov Disord 1997; 12(3): 412–7.
Hikosaka O, Takikawa Y, Kawagoe R. Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 2000; 80(3): 953–78.
Hikosaka O. Role of basal ganglia in saccades. Rev Neurol (Paris) 1989; 145(8–9): 580–6.
Hirose K, Iwasaki Y, Izumi M et al. MM2-thalamic-type sporadic Creutzfeldt–Jakob disease with widespread neocortical pathology. Acta Neuropathol 2006; 112: 503–11.
Hirsch E, Sellal F, Maton B et al. Nocturnal paroxysmal dystonia: a clinical form of focal epilepsy. Neurophysiol Clin 1994; 24(3): 207–17.
Ho L. Hypermetabolism in bilateral basal ganglia in Sydenham chorea on F-18 FDG PET-CT. Clin Nucl Med 2009; 34: 114–6.
Ho M, Chelly J, Carter N et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994; 77: 869–80.
Hodl AK, Hodl E, Otti DV et al. Ideomotor limb apraxia in Huntington's disease: a case-control study. J Neurol 2008; 255(3): 331–9.
Hollerhage M, Matusch A, Champy P et al. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol 2009; 220(1): 133–42.
Holman, AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 2009; 25(3): 425–31.
Holmberg B, Johansson JO, Poewe W et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007; 22: 1138–44.
Holmoy T. Long term effect of gabapentin in stiff limb syndrome: a case report. Eur Neurol 2007; 58: 251–2.
Holt I, Harding A, Petty R et al. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428–33.
Holton JL, Schneider SA, Ganesharajah T et al. Neuropathology of primary adult-onset dystonia. Neurology 2008; 70: 695–9.
Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(Suppl 3): 3–7.
Honnorat J, Cartalat-Carel S et al. Onco-neural antibodies and tumor type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80: 412–6.
Hood AJ, Amador SC, Cain AE et al. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78(6): 565–70.
Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77(2–3): 137–46.
Hooper J and Whittle IR. Long term outcome after thalamotomy for movement disorders in multiple sclerosis. Lancet 1998; 352: 1984.
Hooper J, Taylor R, Pentland B, Whittle IR. A prospective study of thalamic deep brain stimulation for the treatment of movement disorders in multiple sclerosis. Br J Neurosurg 2002; 16: 102–9.
Hornyak M, Feige B, Riemann D, Voderholzer U. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. Sleep Med Rev 2006; 10(3): 169–77.
Hornyak M, Feige B, Voderholzer U, Philipsen A, Riemann D. Polysomnography findings in patients with restless legs syndrome and in healthy controls: a comparative observational study. Sleep 2007; 30(7): 861–5.
Hornyak M, Kotterba S, Trendwalder C. Consensus statement from the German Sleep Society: indications for performing polysomnography in the diagnosis and treatment of restless leg syndrome. Sleep Med 2002; 3(5): 457–8.
Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep 1998; 21(5): 501–5.
Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010; 24(2): 89–98.
Horstink M, Dekker M, Montagna P et al. Pallidopyramidal disease: a misnomer? Mov Disord 2010 ; 25(9): 1109–15.
Horvath J, Fross RD, Kleiner-Fisman G et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19(6): 656–62.
Horvath R, Hudson G, Ferrari G et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006; 129: 1674–84.
Houben MM, Goumans J, van der Steen J. Recording three-dimensional eye movements: scleral search coils versus video oculography. Invest Ophthalmol Vis Sci 2006; 47(1): 179–87.
Houlden H, Baker M, Morris HR et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001; 56(12): 1702–6.
Houlden H, Lincoln S, Farrer M, Cleland PG, Hardy J, Orrell RW. Compound heterozygous PANK2 mutations confirm HARP and Hallervorden–Spatz syndromes are allelic. Neurology 2003; 61(10): 1423–6.
Hounie AG, Pauls DL, do Rosario-Campos MC et al. Obsessive-compulsive spectrum disorders and rheumatic fever: a family study. Biol Psychiatry 2007; 61: 266–72.
Houtchens MK, Benedict RH, Killiany R et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213–23.
Howard FM. A new and effective drug in the treatment of stiff-man syndrome: preliminary report. Mayo Clin Proc 1963; 38: 203–12.
Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999; 366: 127–35.
Hudson G, Chinnery P. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet 2006; 15(Spec No 2): R244–52.
Hudson G, Schaefer AM, Taylor RW et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007; 64: 553–7.
Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497–9.
Hunt JR. Progressive atrophy of the globus pallidus (primary atrophy of pallidal system): a system disease of paralysis agitans type. Brain 1917; 40: 58–148.
Hurwitz TA. Somatization and conversion disorder. Can J Psychiatry 2004; 49: 172–8.
Husby G, Van De Rijn U, Zabriskie JB, Abdin ZH, Williams RC Jr. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144: 1094–110.
Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001; 71: 371–4.
Iannaccone S, Zucconi M, Marchettini P et al. Evidence of peripheral axonal neuropathy in primary restless legs syndrome. Mov Disord 1995; 10(1): 2–9.
Ichiba M, Nakamura M, Kusumoto A et al. Clinical and molecular genetic assessment of a chorea acanthocytosis pedigree. J Neurol Sci 2007; 263: 124–32.
Ikeda Y, Daughters RS, Ranum LP. Bidirectional expression of the SCA8 expansion mutation: one mutation, two genes. Cerebellum 2008; 7(2): 150–8.
Ince P, Wharton S, Shaw P et al. Diseases of movement and system degenerations. In: Ellison D, Louis D, Love S, eds. Greenfield's Neuropathology. 8th ed. London: Arnold Publishing; 2007: 891–1030.
Infante J, Llorca J, Berciano J, Combarros O. Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 2005; 228: 11–13.
Ing Eb, Savino PJ, Bosley TM et al. Hemifacial spasm and osteitis deformans. Am J Ophthalmol 1995; 119: 376–7.
Ingster-Moati I, Bui Quoc E, Pless M et al. Ocular motility and Wilson's disease: a study on 34 patients. J Neurol Neurosurg Psychiatry 2007; 78(11): 1199–201.
Innes JR, Strachan IM, Triger DR. Unilateral Kayser–Fleischer ring. Br J Ophthalmol 1986; 70: 469–70.
Inoue T, Maeyama R, Ogawa H. Hemifacial spasm resulting from cerebellopontine angle lipoma: case report. Neurosurgery 1995; 36: 846–50.
International Classification of Sleep Disorders. American Academy of Sleep Medicine. Diagnostic and Coding Manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005: 1–208.
International Multiple Sclerosis Genetics Consortium, Hafler D, Compston A et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851–62.
Irani S, Lang B. Autoantibody-mediated disorders of the central nervous system. Autoimmunity 2008; 41(1): 55–65.
Iranzo A, Santamaria J, Tolosa E et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004; 63: 930–2.
Ironside JW, Ghetti B, Head MW et al. Prion diseases. In: Ellison D, Louis D, Love S, eds. Greenfield's Neuropathology. 8th ed. London: Arnold Publishing; 2007: 1197–273.
Isaacs H. Stiff-man syndrome in a black girl. J Neurol Neurosurg Psychiatry 1979; 42: 988–94.
Ishikawa J,Takase M, Ohira T et al. Effect of repetitive stimulation on lateral spreads and F-waves in hemifacial spasm. J Neurol Sci 1996; 142: 99–106.
Ishizawa K, Komori T, Sasaki S, Arai N, Mizutani T, Hirose T. Microglial activation parallels system degeneration in multiple system atrophy. J Neuropathol Exp Neurol 2004; 63: 43–52.
Ito T, Ogasawara N. [Autopsy case of progressive atrophy of the globus pallidus]. Rinsho Shinkeigaku 1974; 14: 10–16.
Iwaki A, Kawano Y, Miura S et al. Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J Med Genet 2008; 45(1): 32–5.
Izawa Y, Suzuki H, Shinoda Y. Response properties of fixation neurons and their location in the frontal eye field in the monkey. J Neurophysiol 2009; 102(4): 2410–22.
Jacob PC, Pratap Chand R. Posttraumatic rubral tremor responsive to clonazepam. Mov Disord 1998; 13(6): 977–8.
Jacobs DA, Markowitz CE, Liebeskind DS, Galetta SL. The “double panda sign” in Wilson's disease. Neurology 2003; 61: 969.
Jacques C, Ladouceur R. A prospective study of the impact of opening a casino on gambling behaviours: 2- and 4-year follow-ups. Can J Psychiatry 2006; 51(12): 764–73.
Jagannath A, Wood M. RNA interference based gene therapy for neurological disease. Brief Funct Genomic Proteomic 2007; 6(1): 40–9.
Jain S, Dawson J, Quinn NP, Playford ED. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 2004; 19: 1360–4.
Jankovic J, Friedman DI, Pirozzolo FJ et al. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol 1990; 53: 293–304.
Jankovic J, Friedman DI, Pirozzolo FJ, McCrary JA. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol 1990; 53: 293–304.
Jankovic J, Gilden JL, Hiner BC et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38–48.
Jankovic J, Leder S, Warner D, Schwatz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41: 1088.
Jankovic J, Pardo R. Segmetnal myoclonus. Clinical and pharmacologic study. Arch Neurol 1986; 43: 1025–31.
Jankovic J, Stone L. Dystonic tics in patients with Tourette's syndrome. Mov Disord 1991; 6: 248–52.
Jankovic J. Apraxia of lid opening. Mov Disord 1995; 10(5): 686–7.
Jankovic J. Botulinum toxin in the treatment of tics associated with Tourette's syndrome. Neurology 1993; 43(Suppl 2): A310 [Abstract].
Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol 2001; 85: 15–29.
Jankovic J. Dystonic disorders. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007: 321–47.
Jankovic J. Peripherally induced movement disorders. Neurol Clin 2009; 27(3): 821–32.
Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995; 18: 197–214.
Jankovic J. Treatment of dystonia. Lancet Neurol 2006; 5: 864–72.
Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009; 8: 844–56.
Janssen JC, Lantos PL, Al-Sarraj S et al. Thalamic degeneration with negative prion protein immunostaining. J Neurol 2000; 247: 48–51.
Jarman PR, Wood NW, Davis MT et al. Hereditary geniospasm: linkage to chromosome 9q13-q21 and evidence for genetic heterogeneity. Am J Hum Genet. 1997; 61(4): 928–33.
Jellinger K. [Progressive pallidal atrophy]. J Neurol Sci 1962; 6: 19–44.
Jellinger KA, Seppi K, Wenning GK. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 2003; 106: 188–9.
Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004; 111: 1219–35.
Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18(Suppl 6): S2–12.
Jellinger KA. P25alpha immunoreactivity in multiple system atrophy and Parkinson disease. Acta Neuropathol 2006; 112: 112.
Jellinger KA. Pallidal, pallidonigral and pallidoluysionigral degenerations including associations with thalamic and dentate degenerations. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology. Vol. 5. Amsterdam/New York: Elsevier; 1986: 445–64.
Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease: a postmortem study. Acta Neuropathol 2003; 105: 415–19.
Jellinger KA. Rare neurodegenerative disorders. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia: W.B.Saunders; 1994: 909–31.
Jen JC, Lee H, Cha YH, Nelson SF, Baloh RW. Genetic heterogeneity of autosomal dominant nonprogressive congenital ataxia. Neurology 2006; 67(9): 1704–6.
Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci 2008; 1142: 250–3.
Jeon B, Kim JM, Jeong JM et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998; 65: 60–4.
Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: review of the literature. Schizophr Bull 1979; 5: 251–93.
Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry 1982; 39: 803–16.
Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16: 180–204.
Jimenez-Jimenez FJ, Molina JA. Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors. CNS Drugs 2000; 14: 367–79.
Jimenez-Jimenez FJ, Orti-Pareja M, Yuso-Peralta L et al. Drug-induced parkinsonism in a movement disorders unit: A four-year survey. Parkinsonism Relat Disord 1996; 2: 145–9.
Jinnah HA, Visser JE, Harris JC et al. Delineation of the motor disorder of Lesch–Nyhan disease. Brain 2006 May; 129(Pt 5): 1201–17.
Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord 1995; 10: 714–22.
Johns D. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med 1995; 333: 638–44.
Johnson MA, Kuo YM, Westaway SK et al. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann NY Acad Sci 2004; 1012: 282–8.
Jones HR Jr, Baker RA, Kott HS. Hypertensive putaminal hemorrhage presenting with hemichorea. Stroke 985; 16(1): 130.
Jong S. Kim. Head tremor and stroke. Cerebrovasc Dis 1997; 7: 175–9.
Josephs KA, Boeve BF, Duffy JR et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005; 11(4): 283–96.
Josephs KA, Petersen RC, Knopman DS et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66(1): 41–8.
Jouet M, Rosenthal A, Armstrong G et al. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet 1994; 7(3): 402–7.
Jueptner M, Weiller C. A review of differences between basal ganglia and cerebellar control of movements as revealed by functional imaging studies. Brain 1998; 121(Pt 8): 1437–49.
Jumao-as A, Brenner RP. Myoclonic status epilepticus. Neurology 1990; 40: 1199.
Jung HH, Brandner S. Malignant McLeod myopathy. Muscle Nerve 2002; 26: 424–7.
Jung HH, Hergersberg M, Kneifel S et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001; 49: 384–92.
Jung HH. McLeod syndrome: clinical and neuroradiological aspects. Mov Disord 2005; 20: 1673–94.
Jung KH, Ahn TB, Jeon BS. Wilson disease with an initial manifestation of polyneuropathy. Arch Neurol 2005; 62: 1628–31.
Kabakci K, Hedrich K, Leung JC et al. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology 2004; 62: 395–400.
Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010; 81: 5–12.
Kaji R, Goto S, Tamiya G et al. Molecular dissection and anatomical basis of dystonia: X-linked recessive dystonia-parkinsonism (DYT3). J Med Invest 2005; 52(Suppl): 280–3.
Kalita J, Ranjan P, Misra UK, Das BK. Hemichorea: a rare presentation of tuberculoma. J Neurol Sci 2003; 208: 109–11.
Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) 2003; 168(1–2): 44–56.
Kallweit U, Siccoli MM, Poryazova R, Werth E, Bassetti CL. Excessive Daytime sleepiness in idiopathic restless legs syndrome: characteristics and evolution under dopaminergic treatment. Eur Neurol 2009; 62(3): 176–9.
Kamm C, Healy DG, Quinn NP et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005; 128: 1855–60.
Kanazawa M, Shimohata T, Sato M et al. Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases. Mov Disord 2007; 22(4): 597–8.
Kaneko K, Yoshida K, Arima K et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol 2002; 61(12): 1069–77.
Kanemaru K, Mitani K, Yamanouchi H. Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration. Neurosci Lett 1998; 245(2): 121–2.
Kantor D. 4-Aminopyridine as a treatment for intractable eructation: The First Case Report – American Academy of Neurology 61st Annual Meeting. Seattle, April 2009 (Poster P07.146).
Karageyim AY, Kars B, Dansuk R et al. Chorea gravidarum: a case report. J Matern Fetal Neonatal Med 2002; 12: 353–4.
Kashihara K, Imamura T. Amantadine may reverse punding in Parkinson's disease: observation in a patient. Mov Disord 2008; 23(1): 129–30.
Kassubek J, Sperfeld, AD. Baumgartner A, Huppertz HJ, Riecker A, Juengling FD. Brain atrophy in pure and complicated hereditary spastic paraparesis: a quantitative 3D MRI study. Eur J Neurol 2006; 13: 880–6.
Katayama S, Watanabe C, Khoriyama T et al. Slowly progressive L-DOPA nonresponsive pure akinesia due to nigropallidal degeneration: a clinicopathological case study. J Neurol Sci 1998; 161: 169–72.
Kato S, Nakamura H. Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol 1990; 79: 584–94.
Katsuse O, Iseki E, Arai T et al. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 2003; 106(3): 251–60.
Kaufmann H, Saadia D, Voustianiouk A et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003; 108: 724–8.
Kaufmann P, Shungu D, Sano M et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004; 62: 1297–302.
Kay AH, Adams CBT. Hemifacial spasm: a long term followup of patients treated by posterior fossa surgery and facial nerve wrapping. J Neurol Neurosurg Psychiatry 1981; 4: 1101–3.
Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7(10): 854–68.
Kedia S, Moro E, Tagliati M, Lang AE, Kumar R. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology. 2004; 63(12): 2410–2.
Keller S, Dure LS. Tremor in childhood. Semin Pediatr Neurol 2009; 16: 60–70.
Kenney C, Hunter C, Davidson A et al. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008; 48: 379–84.
Kent DA, Tomasson K, Coryell W. Course and outcome of conversion and somatization disorders. A four-year follow-up. Psychosomatics 1995; 36: 138–44.
Kerber KA, Jen JC, Perlman S, Baloh RW. Late-onset pure cerebellar ataxia: differentiating those with and without identifiable mutations. J Neurol Sci 2005; 238(1–2): 41–5.
Kerbert CW, Margolis MT, Newton TH. Tortuous vertebrobasilar system: a cause of cranial nerve signs. Neuroradiology 1972; 4: 74–7.
Kermadi I, Joseph JP. Activity in the caudate nucleus of monkey during spatial sequencing. J Neurophysiol 1995; 74(3): 911–33.
Khan NL, Giunti P, Sweeney MG et al. Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord 2005; 20: 1115–9.
Khateeb S, Flusser H, Ofir R et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 2006; 79(5): 942–8.
Khiat A, Kuznetsov Y, Blanchet PJ et al. Diffusion-weighted imaging and magnetization transfer imaging of tardive and edentulous orodyskinesia. Mov Disord 2008; 23: 1281–5.
Kim HS, Lee MS. Frequencies of single nucleotide polymorphism in alcohol dehydrogenase7 gene in patients with multiple system atrophy and controls. Mov Disord 2003; 18: 1065–7.
Kim HY, Chung CS, Lee J, Han DH, Lee KH. Hyperventilation-induced limb shaking TIA in Moyamoya disease. Neurology 2003; 60(1): 137–9.
Kim JJ, Kim DJ, Kim TG et al. Volumetric abnormalities in connectivity-based subregions of the thalamus in patients with chronic schizophrenia. Schizophr Res 2007; 97: 226–35.
Kim JS. Delay onset mixed involuntary movements after thalamic stroke. Clinical, radiological and pathophysiological findings. Brain 2001; 124: 299–309.
Kim JS. Involuntary movements after anterior cerebral artery territory infarction. Stroke 2001; 32: 258.
Kim JW, Lee PH. Dystonic head tremor associated with a parietal lesion. Eur J Neurol 2007; 14: e32–3.
Kim Y, Tanaka A, Kimura M et al. Arteriovenous malformation in the cerebellopontine angle presenting as hemifacial spasm. Neurol Med Chir (Tokyo) 1991; 31: 109–12.
Kimmig H, Greenlee MW, Gondan M, Schira M, Kassubek J, Mergner T. Relationship between saccadic eye movements and cortical activity as measured by fMRI: quantitative and qualitative aspects. Exp Brain Res 2001; 141(2): 184–94.
Kimmig H, Ohlendorf S, Speck O et al. fMRI evidence for sensorimotor transformations in human cortex during smooth pursuit eye movements. Neuropsychologia 2008; 46(8): 2203–13.
Kinney HC, Korein J, Panigrahy A et al. Neuropathological findings in the brain of Karen Ann Quinlan. The role of the thalamus in the persistent vegetative state. N Engl J Med 1994; 330: 1469–75.
Kinugawa K, Bidaihet M, Clot F et al. Myoclonus-dystonia: an update. Mov Disord 2009; 24: 479.
Kiriakakis V, Bhatia KP, Quinn NP et al. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998; 121(Pt 11): 2053–66.
Kirkman M, Yu-Wai-Man P, Korsten A et al. Gene-environment interactions in Leber hereditary optic neuropathy. Brain 2009; 132: 2317–26.
Kirkwood SC, Siemers E, Stout JC et al. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol 1999; 56(5): 563–8.
Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007; 178: 7412–21.
Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9: 914–20.
Kiskiniemi M, Van Vleymen B, Hakamies L et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomized, double blind, crossover study comparing the safety and efficacy of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998; 64: 344–8.
Kitzberger R, Madl C, Ferenci P. Wilson disease. Metab Brain Dis 2005; 20(4): 295–302.
Kjersti Erichsen A, Koht J, Stray-Pedersen A et al. Prevalence of hereditary ataxia and spastic paraplegia in Southeast Norway: a population based study. Brain 2009; 132: 1577–88.
Klaffke S, Kuhn AA, Plotkin M et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 2006; 21(10): 1724–7.
Klebe S, Stolze H, Kopper F et al. Gait analysis of sporadic and hereditary spastic paraplegia. J Neurol 2004; 251: 571–8.
Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Semin Neurol 1999; 19: 271–80.
Kloppel S, Draganski B, Golding CV et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 2008; 131(Pt 1): 196–204.
Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11: 381–6.
Kluger BM, Fernandez HH. Management of non-motor manifestations of Parkinson's disease. In: Pahwa R, Simuni T, eds. Parkinson's Disease. New York: Oxford University Press; 2009: 83–94.
Knight MA, Hernandez D, Diede SJ et al. A duplication at chromosome 11q12.2–11q12.3 is associated with spinocerebellar ataxia type 20. Hum Mol Genet 2008; 17(24): 3847–53.
Knobel D, Aybek S, Pollo C, Vingerhoets FJ, Berney A. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson Disease: a case report. Cogn Behav Neurol 2008; 21(3): 187–9.
Knutsson E. An analysis of Parkinsonian gait. Brain 1972; 95: 475–86.
Kobayashi H, Garcia CA, Alfonso G et al. Molecular genetics of familial spastic paraplegia: a multitude of responsible genes. J Neurol Sci 1996; 137: 131–8.
Kobayashi J, Nagao M, Kawata A et al. A case of late adult-onset dentatorubral-pallidoluysian atrophy mimicking central pontine myelinolysis. J Neurol 2009; 256: 1369–71.
Kollensperger M, Geser F, Seppi K et al. Red flags for multiple system atrophy. Mov Disord 2008; 23: 1093–9.
Kollensperger M, Stampfer-Kountchev M, Seppi K et al. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 2007; 14: 66–72.
Kollensperger M, Wenning GK. Assessing disease progression with MRI in atypical parkinsonian disorders. Mov Disord 2009; 24(Suppl 2): S699–S702.
Koller W, Lang A, Vetere-Overfield B et al. Psychogenic tremors. Neurology 1989; 39: 1094–9.
Koller W, O'Hara R, Durus W, Bauer J. Tremor in chronic alcoholism. Neurology 1985; 35: 1660.
Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985; 35: 1450–4.
Kompoliti K, Goetz CG, Boeve BF et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55(7): 957–61.
Kong CK, Ko CH, Tong SF, Lam CW. Atypical presentation of dopa-responsive dystonia: generalized hypotonia and proximal weakness. Neurology 2001; 57: 1121–4.
Konishi Y, Shirabe T, Katayama S et al. Autopsy case of pure akinesia showing pallidonigro-luysian atrophy. Neuropathology 2005; 25: 220–7.
Koran LM, Faber RJ, Aboujaoude E, Large MD, Serpe RT. Estimated prevalence of compulsive buying in the United States. Am J Psychiatry 2006; 163: 1806–12.
Korn-Lubetzki I, Brand A, Steiner I. Recurrence of Sydenham chorea: implications for pathogenesis. Arch Neurol 2004; 61: 1261–4.
Kosaka K, Oyanagi S, Matsushita M et al. Multiple system degeneration and involving thalamus, reticular formation, pallido-nigral, pallido-luysian and dentato-rubral systems. A case report. Acta Neuropathol 1977; 39: 89–95.
Kotterba, S., Tegenthoff, M., Malin, J.-P. Hemifacial spasm or somatoform disorder: postexcitatory inhibition after transcranial magnetic cortical stimulation as a diagnostic tool. Acta Neurol Scand 2000; 101: 305–10.
Kovacs GG, Gelpi E, Lehotzky A et al. The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. Acta Neuropathol 2007; 113: 153–61.
Kowal L, Davies R, Kiely P. Facial muscle spasms: an Australian study. Australian and N Z J Ophthalmol 1998. 26: 123–8.
Koyama M, Yagishita A, Nakata Y, Hayashi M, Bandoh M, Mizutani T. Imaging of corticobasal degeneration syndrome. Neuroradiology 2007; 49(11): 905–12.
Krack P, Marion MH. “Apraxia of lid opening,” a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994; 9(6): 610–5.
Krakauer M, Law I. FDG PET brain imaging in neuropsychiatric systemic lupus erythematosus with choreic symprtoms. Clin Nucl Med 2009; 34: 122–3.
Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405–10.
Krasnianski A, Bartl M, Sanchez Juan PJ et al. Fatal familial insomnia: clinical features and early identification. Ann Neurol 2008; 63: 658–61.
Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 2006; 129: 2288–96.
Krauss G, Mathews G. Similarities in mechanisms and treatments for epileptic and nonepileptic myoclonus. Epilepsy Curr 2003; 3(1): 19–21.
Krauss JK, Weigel R, Blahak C et al. Chronic spinal cord stimulation in medically intractable orthostatic tremor. J Neurol Neurosurg Psychiatry 2006; 77(9): 1013–16.
Kraybill ML, Larson EB, Tsuang DW et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64: 2069–73.
Kremer M. Sitting, standing, and walking. Br Med J 1958; 2(5088): 63–8.
Kruszewski SP, Shane J. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2007; 68(19): 1641; author reply 2.
Kubota A, Hida A, Ichikawa Y et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype–phenotype correlations. Mov Disord 2009; 24(3): 441–5.
Kugelmass N. Stiff-man syndrome in a child. NY State J Med 1961; 61: 2483–7.
Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 2007; 29(7): 450–3.
Kulisevsky J, Marti MJ, Ferrer I et al. Meige syndrome: neuropathology of a case. Mov Disord 1988; 3: 170–5.
Kumar H, Masiowski P, Jog M. Chorea in the elderly with mutation positive polycythemia vera: a case report. Can J Neurol Sci 2009; 36: 370–2.
Kumar N, Boes CJ, Babovic-Vuksanovic D, Boeve BF. The “eye-of-the-tiger” sign is not pathognomonic of the PANK2 mutation. Arch Neurol 2006; 63(2): 292–3.
Kumar N. Copper deficiency myelopathy: human swayback. Mayo Clin Proc 2006; 81: 1371–84.
Kumar R, Bergeron C, Pollanen M, Lang AE. Cortical-basal ganglionic degeneration. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 3rd ed. Baltimore, MD: William & Wilkins; 1998. 297–316.
Kumar TS, Moses PD. Isolated tongue involvement – an unusual presentation of Wilson's disease. J Postgrad Med 2005; 51: 337.
Kummer A, Maia DP, Cardoso F, Teixeira, AL. Trichotillomania in acute Sydenham's chorea. Aust NZ J Psychiatry 2007; 41: 1013–4.
Kung AW. Neuromuscular complications of thyrotoxicosis. Clin Endocrinol (Oxf) 2007; 67(5): 645–50.
Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Dis 2008; 23(4): 616–19.
Kupsch A, Benecke R, Muller J et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355(19): 1978–90.
Kupsch A, Benecke R, Muller J et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355: 1978–90.
Kurian MA, Morgan NV, MacPherson L et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70(18): 1623–9.
Kurian MA, Morgan NV, MacPherson L et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70(18): 1623–9.
Kurlan R, Behr J, Medved L, Como PG. Transient tic disorder and the clinical spectrum of Tourette's syndrome. Arch Neurol 1988; 45: 1200–1.
Kurlan R, Behr J, Medved L, Shoulson I. Myoclonus and dystonia: a family study. Adv Neurol 1988; 50: 385.
Kurlan R, Brin MF, Fahn S. Movement disorder in reflex sympathetic dystrophy: a case proven to be psychogenic by surveillance video monitoring. Mov Disord 1997; 12: 243–5.
Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356–63.
Kurlan R, Daragjati C, McDermott MP et al. Complex socially inappropriate behavior in Tourette's syndrome. J Neuropsychiatry Clin Neurosci 1996; 8: 311–17.
Kurlan R, Lichter D, Hewitt D. Sensory tics in Tourette's syndrome. Neurology 1989; 39: 731–4.
Kurlan R, McDermott MP, Deeley C. Prevalence of tics in school children and association with placement in special education. Neurology 2001; 57: 1383–8.
Kurlan R. Tourette's syndrome: current concepts. Neurology 1989; 39: 1625–30.
Kushida C, Martin M, Nikam P et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007; 16(4): 617–24.
Kwack C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol 2003; 60: 1595–8.
Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord 2002; 17(4): 821–5.
Kyriakouli D, Boesch P, Taylor R et al. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther 2008; 15: 1017–23.
Lader, M. Antiparkinsonian medication and pathological gambling. CNS Drugs 2008; 22(5): 407–16.
LaFrance WC, Jr., Friedman JH. Cognitive behavioral therapy for psychogenic movement disorder. Mov Disord 2009; 24: 1856–57.
Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21: 704–7.
Lagier-Tourenne C, Tazir M, Lopez LC N et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 2008; 82(3): 661–72.
Lajoie Y, Barbeau H, Hamelin M. Attentional requirements of walking in spinal cord injured patients compared to normal subjects. Spinal Cord 1999; 37: 245–50.
Lamperti C, Naini A, Hirano M et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003; 60: 1206–8.
Lance JW, Adams RD. The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 1963; 86: 111–36.
Landau WM, Mink JW. Is decreased dexterity in Parkinson disease due to apraxia? Neurology 2007; 68(2): 90–1.
Lang AE, Lozano A, Duff J et al. Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration. Adv Neurol 1997; 74: 199–211.
Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3(5): 309–16.
Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia: W.B. Saunders; 1994; 977–94.
Lang AE. Miscellaneus drug-induced movement disorders. In: Lang AE, Weiner WJ, eds. Drug-induced Movement Disorders. Mount Kikco: Futura; 1992: 339–81.
Lang AE. Psychogenic dystonia: a review of 18 cases. Can J Neurol Sci 1995; 22: 136–43.
Lange E, Poppe W, Scholtze P. Familial progressive pallidum atrophy. Eur Neurol 1970; 3: 265–7.
Lange E, Poppe W. [Clinical contribution to the pathological aspect of progressive atrophy of the pallidum (Van Bogaert).]. Psychiatr Neurol (Basel) 1963; 146: 176–92.
Langstrom N, Hanson RK. High rates of sexual behavior in the general population: correlates and predictors. Arch Sex Behav 2006; 35(1): 37–52.
Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998; 57: 1099–111.
Lapierre O, Montplaisir J. Polysomnographic features of REM-sleep behavior disorder: development of a scoring method. Neurology 1992; 42: 1371–4.
Lapresle J. La voie dento-olivaire: sa mise en evidence, son trajet, sa signification. Bull Acad Natl Med 1984; 168: 336–41.
Larsen S, Telstad W, Sorensen O, Thom E, Stensrud P, Nyberg-Hansen R. Carbamazepine therapy in restless legs. Discrimination between responders and non-responders. Acta Med Scand 1985; 218(2): 223–7.
Larsson BW, Kadi F, Ulfberg J, Aulin KP. Skeletal muscle morphology in patients with restless legs syndrome. Eur Neurol 2007; 58(3): 133–7.
Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999; 60(4): 241–4.
Laureys S, Salmon E, Garraux G et al. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 1999; 246(12): 1151–8.
Lavin MF, Gueven N, Grattan-Smith P. Defective responses to DNA single- and double-strand breaks in spinocerebellar ataxia. DNA Repair (Amst). 2008; 7(7): 1061–76.
Lazurova I, Macejova Z, Benhatchi K et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin Rheumatol 2007; 26: 2145–7.
Le Ber I, Moreira MC, Rivaud-Pechoux S et al. Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain 2003; 126(Pt 12): 2761–72.
Leckman JF, Zhang H, Vitale A et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998; 102: 14–19.
Lee H, Tsai C, Chi C et al. Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol 2009; 40: 88–93.
Lee JE, Shin HW, Kim KS, Sohn YH. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord 2009; 24(4): 579–82.
Lee LV, Pascasio FM, Fuentes FD et al. Torsion dystonia in Panay, Philippines. Adv Neurol 1976; 14: 137–51.
Lee MS, Lyoo CH, Lee HJ, Kim YD. Hemichoreoathetosis following posterior parietal watershed infarction: was striatal hypoperfusion really to blame? Mov Disord 2000; 15(1): 178–9.
Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 1994; 9: 493–507.
Lee PH, Nam HS, Lee KY, Lee BI, Lee JD. Serial brain SPECT images in a case of Sydenham chorea. Arch Neurol 1999; 56: 237–40.
Lee S, Sha Q, Wu X et al. Expression Profiles of Mouse Kell, XK, and XPLAC mRNA. J Histochem Cytochem 2007; 55: 365–74.
Lee SJ, Kim JS, Song IU, An JY, Kim YI, Lee KS. Poststroke restless legs syndrome and lesion location: anatomical considerations. Mov Disord 24(1): 77–84.
Lee WY, Jin DK, Oh MR et al. Frequency analysis and clinical characterization of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Korean patients. Arch Neurol 2003; 60: 858–63.
Lees AJ, Bannister R. The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy–Drager syndrome). J Neurol Neurosurg Psychiatry 1981; 44: 347–51.
Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951; 14: 216–21.
Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA. Abnormal ocular motor control in Huntington's disease. Neurology 1983; 33(10): 1268–75.
Leigh RJ, Zee DS. The Neurology of Eye Movements. 4th ed. Oxford: Oxford University Press; 2006.
Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD. The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry 1994; 57(4): 455–9.
Leiguarda R, Merello M, Balej J et al. Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. Mov Disord 2000; 15(4): 627–40.
Leiguarda R, Merello M, Balej J. Apraxia in corticobasal degeneration. Adv Neurol 2000; 82: 103–21.
Leiguarda R. Limb apraxia: cortical or subcortical. Neuroimage 2001; 14(1 Pt 2): S137–41.
Leiguarda RC, Merello M, Nouzeilles MI et al. Limb-kinetic apraxia in corticobasal degeneration: clinical and kinematic features. Mov Disord 2003; 18(1): 49–59.
Leiguarda RC, Pramstaller PP, Merello M et al. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997; 120 (Pt 1): 75–90.
Lejoyeux M, Bailly F, Moula H, Loi S, Adès J. Study of compulsive buying in patients presenting obsessive-compulsive disorder. Comp Psychiatry 2005; 46(2): 105–10.
Lempert T, Brandt T, Dieterich M, Huppert D. How to identify psychogenic disorders of stance and gait. A video study in 37 patients. J Neurol 199; 238: 140–6.
Lennox G, Jones R. Gaze distractibility in Wilson's disease. Ann Neurol 1989; 25(4): 415–7.
Lepore FE, Duvoisin RC. “Apraxia” of eyelid opening: an involuntary levator inhibition. Neurology 1985; 35(3): 423–7.
Lernmark A. Glutamic acid decarboxylase: gene to antigen to disease. J Intern Med 1996; 240(5): 259–77.
Lesniak M, Czlonkowska A, Seniow J. Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson's disease. Mov Disord 2008; 23(14): 2067–73.
Lesser RP, Fahn S. Dystonia: a disorder often misdiagnosed as a conversion reaction. Am J Psychiatry 1978; 135: 349–52.